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IAbstractProtein aggregation and formation of insoluble aggregates in central nervous system is the maincause of neurodegenerative disease. Parkinson’s disease is associated with the appearance ofspherical masses of aggregated proteins inside nerve cells called Lewy bodies. α-Synuclein is themain component of Lewy bodies. In addition to α-synuclein, there are more than a hundred of otherproteins co-localized in Lewy bodies: 14-3-3η protein is one of them. In order to increase ourunderstanding on the aggregation mechanism of α-synuclein and to study the effect of 14-3-3η onit, I addressed the following questions. (i) How α-synuclein monomers pack each other duringaggregation? (ii) Which is the role of 14-3-3η on α-synuclein packing during its aggregation? (iii)Which is the role of 14-3-3η on an aggregation of α-synuclein “seeded” by fragments of its fibrils?In order to answer these questions, I used different biophysical techniques (e.g., Atomicforce microscope (AFM), Nuclear magnetic resonance (NMR), Surface plasmon resonance (SPR) andFluorescence spectroscopy (FS)).To answer the first question, I compared by AFM imaging the in vitro aggregation of α-synuclein with that of α-synuclein dimers (NC-, NN-, and CC-terminal dimers) and with that of a so-called Synucle-Nuclein construct. The Synucle-Nuclein construct is a dimer where an α-synucleinmoiety lacking N-terminal region (Synucle) is connected to another moiety of α-synuclein lacking C-terminal region (Nuclein). In this construct the two NAC (Non Amyloid-beta Component) regionsthat drive the formation of β-sheet like structure in the fibrils are tethered together, contrary to thecases of the other three dimers. I found that only the NC-terminal dimer aggregates into maturefibrils like α-synuclein does, whereas both NN- and CC-terminal dimers form amorphousaggregates. Also the Synucle-Nuclein construct aggregates into mature fibrils, but they are shorterin length than those of α-synuclein. This is a strong indication that in α-synuclein fibrils themonomer moieties are packed in a head to tail fashion, and that the NAC β-sheet packing is the coreof the fibrils.To answer the second question, I studied the in vitro aggregation of α-synuclein and α-synuclein dimers in the presence of different molar concentration of 14-3-3η. Imaging with AFM, Ifound that 14-3-3η affects the aggregation pathway of α-synuclein by modifying the shape of thegrowing oligomers and protofibrils. NMR and SPR revealed that 14-3-3η does not interact with α-synuclein monomer. AFM showed that 14-3-3η does not interact also with α-synuclein maturefibrils. In order to prove that 14-3-3η targets the oligomeric species, I labeled both α-synuclein and14-3-3η with a fluorophore, and by FS I could demonstrate that 14-3-3η intercalates into thegrowing oligomers both in the case of α-synuclein and in the case of NC-terminal dimers. This result
II
was confirmed by the data obtained on trying to answer the third question, when I studied α-synuclein aggregation in the presence of both 14-3-3η and fragments of α-synuclein mature fibrils.These fragments were prepared by ultrasonication of α-synuclein mature fibrils. By exposing their“living ends”, they can favor and “seed” the aggregation of monomeric α-synuclein.  Imaging withAFM, I found that 14-3-3η slows down the addition of monomeric α-synuclein to the exposed livingends of those seeds. These AFM data on the growth of α-synuclein seeds in the presence of 14-3-3ηand those obtained by FS on the inclusion of 14-3-3η into the growing oligomers and fibrils of α-synuclein demonstrate that the 14-3-3η can inhibit the α-synuclein aggregation by an intercalationmechanism. This capability might explain the co-localization of 14-3-3η and α-synuclein in Lewybodies.
Key words: α-Synuclein, Aβ-protein, 14-3-3η, Neurodegenerative disease, Protein aggregation,AFM etc.
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Chapter-1
(Introduction)
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Neurodegenerative disease is a group of brain related disorder. They involve in the damage anddeath of neuronal cells in nervous system associated with the protein misfolding and aggregation,which affect the normal function of human brain. In general, neuronal cell death and damageoriginates by the aggregation of misfolded proteins into the beta sheet like structure in the nervoussystem. There are several factors that influence the aggregation and accumulation of misfoldedproteins into the beta sheet like structure, whereas the exact relation between protein aggregationand and cell death is still not very well understood.
[1.1] Protein misfolding in neurodegenerative diseaseMost of the neurodegenerative diseases are associated with the misfolding of intrinsicallyunstructured proteins into β-sheet like structures. The intrinsically unstructured proteins acquiredifferent conformations when they aggregate to form β-sheet like structure [Sandal et al., 2008].These conformations are stabilized by the intermolecular interactions, leading to the formation ofoligomers, proto-ﬁbrils and ﬁbrils, and finally mature fibrils accumulate as amyloid deposits inaffected tissues [Soto et al., 2003; Soto et al., 2008].  Aggregates of amyloid-beta (Aβ) in alzheimer’sdisease (AD) and prion protein (PrPSc) in prion diseases accumulate extracellularly, and othermisfolded aggregates accumulate intracellularly, such as α-synuclein in parkinson’s disease (PD),superoxide dismutase (SOD) in amyotrophic lateral sclerosis (ALS), tau in tauopathies or AD, andhuntingtin (HTT) in huntington disease (HD) [Soto, 2003].
[1.1.1] Role of misfolded proteins in neurodegenerative diseaseOver the past two decades misfolded proteins have been widely considered to be the triggeringfactors in the neurodegenerative disease (e.g. PD, AD, HD, Prion Disease etc.). Perhaps the mostconvincing pieces of evidence in favor of this observation came from genetic studies. Most of theneurodegenerative diseases mainly arise sporadically, without detectable genetic origins; however,a portion (usually small) of the cases can be inherited (e.g. A30P, E46K, A53T mutations in α-synuclein). Interestingly, mutations in the genes encoding the protein component of the misfoldedaggregates have been shown to be genetically associated with inherited forms of the disease[Selkoe et al., 1996; Buxbaum et al., 2000; Hardy, 2001; Soto, 2001]. The familial forms usually havean earlier onset and higher severity than sporadic cases.  Mutations in the respective misfoldedproteins have been associated with familial forms of many diseases, including PD, AD, HD, ALS andvarious rarer amyloid-related diseases such as cerebral haemorrhage with amyloidosis of the dutchand icelandic type, and cerebral amyloidosis of the British and Danish type [Selkoe et al., 1996;
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Buxbaum et al., 2000; Hardy,2001; Soto, 2001]. The fact that mutations in the genes encoding themisfolded proteins produce inheritable disease is by itself a very strong argument for a crucial roleof protein misfolding in the disease.Other evidence for the important role of protein misfolding came from the studies aiming togenerate transgenic animal models for protein misfolded diseases (PMDs). Insertion of humangenes encoding mutant proteins with a high propensity to misfold and aggregate leads to theemergence of several pathological hallmarks of the different diseases. Human α-synuclein geneexpression in transgenic mice induces some of the hallmarks of PD, as dopaminergic cell loss, Lewy-body accumulation and motor dysfunction [Meredith et al., 2008]. In case of prion protein, micegenerate spontaneous neurodegeneration accompanied by brain vacuolization as happens innatural transmissible spongiform encephalopathy (TSEs) [DeArmond et al., 1995]. In the case ofAD, the most common transgenic models over-express the amyloid precursor protein (APP) and/orthe presenilin 1 (PS1), both genes associated to familial forms of AD [Selkoe 1996]. Transgenic miceexpressing human mutated APP show amyloid plaques, cognitive impairment, cell death andrelated inﬂammatory processes [Duyckaerts et al., 2008]. All these ﬁndings suggest that misfoldingand aggregation of amyloid proteins play an essential role in the pathology and could be the maincause of Neurodegenerative disease.
[1.1.2] Mechanisms of protein misfoldingProtein misfolding arises from the imperfect folding process that results in the formation of theproteins with different conformations from its native state [Sandal et al., 2008]. Protein misfoldingcan go on by several reasons [Soto, 2001; Kelly, 1996]. (i) Somatic mutations in the gene sequenceleading to the production of a protein unable to adopt the native folding. (ii) Errors on theprocesses of transcription or translation leading to the production of modiﬁed proteins unable toproperly fold. (iii) Failure of the folding and chaperone machinery. (iv) Mistakes on the post-translational modiﬁcations or trafﬁcking of proteins.  (v) Structural modiﬁcation produced byenvironmental changes. (vi) Induction of protein misfolding by seeding and cross-seedingmechanisms.The most common destiny for misfolded proteins is self-aggregation, because the mistakenexposure of fragments to the solvent that are normally buried inside the protein, lead to a highdegree of stickiness. The β-sheet structural motif offers the most favorable organization for theseintermolecular aggregates and can accommodate an almost unlimited number of polypeptidechains [Kelly, 1996; Nelson et al., 2005].  As a result, misfolded proteins exist as a large and
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heterogenous range of polymeric sizes, which are usually classiﬁed in very well deﬁned categories,such as oligomers, protoﬁbrils and ﬁbrils [Caughey et al., 2003; Glabe, 2006; Walsh et al., 2007].Soluble oligomers are small assemblies of misfolded proteins that are present in the buffer solublefraction of tissue extracts and usually include structures ranging in size from dimers to 24-mers[Glabe, 2006; Walsh et al., 2007]. Recent undeniable facts coming from several autonomous studiesof different proteins indicates that oligomers might be the most toxic species in the misfolding andaggregation pathway [Caughey et al., 2003; Glabe, 2006; Walsh et al., 2007]. Protoﬁbrils are largeraggregates that can be seen by using electron microscopy and atomic force microscopy as curvi-linear structures of 4–11 nm diameter and <200 nm long [Caughey et al., 2003; Walsh et al., 1999].Protoﬁbrils increase in size with increased time and protein concentration, and are lengthened bygrowth on their ends [Harper et al., 1999].  Annular protoﬁbrils are pore-like assemblies thataccumulate in the cell membrane and may contribute to cell death [Srinivasan et al., 2004; Lashuelet al., 2002]. Protoﬁbrils and annular protoﬁbrils have also been shown to be highly toxic in various
in vitro studies [Lashuel et al., 2002; Hartley et al., 1999]. Amyloid ﬁbrils are long, straight andunbranched structures of around 10 nm diameter and usually several micrometers lengths [Nelsonet al., 2005]. They bind the dies Congo red and thioﬂavin and show a typical “cross-β” X-raydiffraction pattern consisting of two major reﬂections at 4.7 Å and 10 Å found on orthogonal axes[Nelson et al., 2005]. Fibrils can also elicit toxicity in cultured cells, but usually at much higherconcentrations than oligomers and protoﬁbrils [Caughey et al., 2003].
[1.1.3] Protein misfolding in the presence of seedsThe mechanism of protein misfolding and aggregation in the presence of seeds (fragmented maturefibrils) is called as “seeding-nucleation” model [Soto et al., 2006; Jarrett et al., 1993]. In this process,the early steps of misfolding are thermodynamically unfavorable and progress gradually, until theminimum stable oligomeric unit is formed, then grows exponentially at a fast speed. There are twokinetic phases in the seeding-nucleation model of polymerization. Firstly, during the lag phase, alow amount of misfolded and oligomeric structures are produced in a slow process, generatingseeds for the next step. Once nuclei are formed, the elongation phase takes place and results in fastgrowing of the polymers. The addition of pre-formed seeds can reduce the length of the lag phase,accelerating the exponential phase. Fragmented fibrils are considered as the best seeds topropagate the misfolding process in an exponential manner.
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[1.1.4] Protein aggregation in neurodegenerative diseaseProtein aggregation is the principle phenomena of amyloid like proteins in neurodegenerativediseases such as PD, AD and Prion disease.  The rate of morbidity and mortality is higher in thedeveloped world [Hebert et al., 2001; Hebert et al., 2003]. Largely as a result of increased lifeexpectancy and changing population demographics, neurodegenerative dementias andneurodegenerative movement disorders are becoming more common [Brookmeyer et al., 1998;Samii et al., 2004]. Converging lines of investigation have revealed a potential single commonpathogenic mechanism underlying many diverse neurodegenerative disorders (i.e., the aggregationand deposition of misfolded proteins). As summarized in Table 1.1, nearly every majorneurodegenerative disease is characterized pathologically by the insidious accumulation ofinsoluble filamentous aggregates of normally soluble proteins in the central nervous system (CNS).Because these filamentous aggregates display the ultrastructural and tinctorial properties ofamyloid (i.e., 10 nm wide fibrils with crossed β-sheet structures), these diseases can be groupedtogether as brain amyloidoses.From a pathological point of view, neurodegenerative entities are defined by the type andpattern of amyloid deposition in the brain. Unfortunately, the type and pattern of brain amyloidosisdoes not always correlate well with the observed clinical phenotype. This disconnect has led to aconfusing nosology that sometimes requires clinicians to describe phenotypes on the basis of thepresumed presence of pathological lesions (e.g., dementia with Lewy bodies) and sometimesrequires pathologists to describe lesions using clinical language regardless of the patient’s actualclinical presentation (e.g., progressive supranuclear palsy, PSP).  The best way to circumvent thischaos may be the use of chemical analytes of biological fluids and neuroimaging biomarkers thatallow clinicians to distinguish between these related brain amyloidoses on the basis of the natureand extent of the brain pathology as well as the specific amyloidogenic protein(s) involved indisease pathogenesis.Recognizing that all these related neurodegenerative diseases share common mechanismsinvolving CNS accumulation of misfolded proteins suggests that these disorders may have similartargets for the development of diagnostic and therapeutic agents.
Table 1.1: Common neurodegenerative diseases characterized by deposition of aggregated
proteins
Neurodegenerative Disease Related ProteinsAlzheimer’s disease Amyloid-β (Aβ), α-Synuclein, TauAmyotrophic lateral sclerosis Superoxide dismutase-1 (SOD1)
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Cortical basal degeneration/Progressivesupranuclear palsy TauDementia with Lewy Bodies α-SynucleinHuntington disease Huntingtin (containing polyglutamine repeatexpansion)Multiple system Atrophy α-SynucleinParkinson’s disease α-SynucleinPick’s disease TauPrion diseases Protease-resistant prion protein (PrP)Spinocerebellar ataxia Ataxin (containing polyglutamine repeatexpansion)
[1.1.5] General mechanisms of brain amyloid formationBrain amyloidosis begins with the production of a soluble native protein that is misfolded to yieldthe precursor for fibril formation (Figure 1.1). The misfolded protein can self-aggregate to formoligomers, protofibrils, or other intermediates that promotes fibril formation [Caughey et al., 2003].Oligomers of Aβ can be detected in vitro [Huang et al., 2000], in cell culture and transgenic mousemodels of Alzheimer’s disease [Walsh et al., 2000; Podlisny et al., 1998; Takahashi et al., 2004], andin postmortem Alzheimer’s disease brain specimens [Kayed et al., 2003].
Figure 1.1: Model for protein misfolding and fibrillization. Soluble native protein is misfolded and
associates in the form of oligomers and other intermediates that eventually give rise to fibrils. Potential
opportunities for theapeutic intervention are shown in blue boxes. [Reproduced from Skovronsky et al. 2006]
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Although, oligomers of α-synuclein have been studied very well, it is obvious that otheramyloidogenic proteins such as Aβ or polyglutamine-containing proteins can also form oligomers.Remarkably, oligomers composed of each of these amyloidogenic proteins (which share no primarysequence homology) show a similar conformation-dependent structure [Kayed et al., 2003]. Thesestudies may suggest a common mechanism of amyloid formation that depends upon structuraldeterminants within the oligomers. Further support of this hypothesis, the observation comes fromthe different forms of amyloid that interact with each other in vitro. For example, α-synuclein caninitiate fibrillization of tau, and co-incubation of tau and α-synuclein synergistically promotesfibrillization of both proteins [Giasson et al., 2003].There are various factors that influence the balance between native protein, misfoldedprotein, oligomers, and fibrils both in vivo and in vitro. For example, in the disease state,overproduction of the amyloidogenic protein constituent, wrong covalent bond modification, faileddegradation, or insufficient molecular chaperone activity may all contribute in shifting the balancetowards misfolded protein and oligomer formation. Each of these steps represents a potentialtarget for therapeutic intervention, with therapies being developed currently for different forms ofamyloid.
[1.2] Biophysical techniquesThere are several techniques that can be used for the study of protein aggregation and itscharacterization. Eeach techniques have their own advantages and disadvantages. These techniquesare summarized in Table 1.2 and in detail [see review in Morris et al., 2009]. Methods indicated in
Table 1.2 is if the physical methods listed there are used as direct or indirect1 methods for thesystems at hand, and if they can be used in-situ or involve ex-situ use and sample preparation. Inprotein aggregation, as with all science, the use of multiple, complimentary, ideally direct, in-situphysical methods are of course preferred.In this thesis we have used the Atomic Force Microscope (AFM) and Fluorescencepolarization (FP) to study the aggregation of α-synuclein. Apart from the AFM and FP we have alsoused ultrasonic sonicator to prepare seeds from the mature fibrils of α-synuclein.
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Table 1.2: Physical methods used in the literature to analyze protein aggregation (In detail See
review in Morris et al., 2009)
S.No Method Direct/
Indirect1
In-situ/Ex-
situ
Measure
Kinetics?
Selected
References
1. Atomic force microscopy Direct In-situ Yes Harper et al.,1997
2. Calorimetry Direct In-situ Yes Bondos et al.,2006
3. Circular dichroism Direct ConcentrationDependenta Yes Woody et al.,1996
4. Dyes Indirect ConcentrationDependenta Yes Munishkina etal., 2007
5. Electron microscopy Direct Ex-situ No Bondos et al.,2006
6. Electron paramagneticresonance spectroscopy Indirect ConcentrationDependenta Yes Lundberg et al.,1997
7. Flow birefringence Direct In-situ Yes Kasai et al.,1972
8. Fluorescence spectroscopywith an intrinsic fluorophore Direct ConcentrationDependenta Yes Munishkina etal., 2007
9. Fluorescence spectroscopywith an extrinsic fluorophore Indirect ConcentrationDependenta Yes Munishkina etal., 2007
10. Fourier transform infraredSpectroscopy Direct ConcentrationDependenta Yes Bondos et al.,2006
11. Light scattering Direct In-situ Yes Lomakin et al.,1997
12. Mass spectrometry Direct Ex-situ No Lashuel et al.,2002
13. Nuclear magnetic resonanceSpectroscopy Direct ConcentrationDependenta Yes Fernandez etal., 2004
14. Quartz crystal oscillatorMeasurements Direct ConcentrationDependenta Yes Knowles et al.,2007
15. Turbidity Direct In-situ Yes Beme et al.,1974
16. Viscosity Direct In-situ Yes Harding et al.,1997
17. X-ray diffraction Direct ConcentrationDependenta Nob Sunde et al.,1997
1We were unable to find a definition for direct vs. indirect physical methods in the literature. Therefore, we will
use the term direct physical method to mean a method that measures a property that is directly affected by the
aggregation process, while an indirect method measures a property that is only indirectly affected by the
aggregation process
aBy “concentration dependent” we mean this method can be in-situ if the aggregation conditions are within the
detection limits of the physical method.
bOr “yes” in principle if Synchrotron radiation is used.
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[1.2.1] Atomic force microscopeAtomic force microscope (AFM) is a technique to explore the molecular behavior, molecularmotions, fluctuations and growth of the molecule (both biological and non-biological) at nano-scalelevel.  AFM is a member of the scanning probe microscopes family; it was developed by Gerd Binnigand Carl Quate in 1986 at IBM research laboratory Zurich and at Stanford, Ca respectively.  AFM isderived from the scanning tunneling microscope (STM), where a sharp metal tip is scanned over aconducting surface detecting minute changes in sample topography through the strong distancedependence of the tunneling current.  Atomic force microscopy relies on the tip-sample interactionforces for topography contrast. These forces are nonspecific and do not require conductive samples,a major limitation of STM in the study of biomaterials.The working principle of AFM is that a small cantilever (typical length ~100 μm) with asharp tip (1-10 nm end-of-curvature) scans a sample surface. As the tip encounters heightdifferences or experiences changing tip-sample interaction forces, the cantilever bends (Figure
1.2). This deflection is detected and a feedback system moves the probe to keep the deflection at aset value. In tapping mode AFM, the cantilever is oscillated, and feedback is usually done on eitherthe tapping amplitude or frequency signal. In this way, an AFM maps the nanometer to micrometerscale topography and surface properties of the sample in a less invasive way.
Figure 1.2:Working principle of tapping mode atomic force microscopy. This simplified schematic gives an
overview of the main components of a beam deflection type AFM in amplitude-modulation tapping mode and
explains the origins of the signals that will be referred to in the text. Comparing the amplitude signal with a pre-
set setpoint value yields the error signal. The feedback electronics uses this signal to adjust the voltage to the z-
piezo, changing the height of the cantilever relative to the surface. Meanwhile, the phase detector compares the
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phase of the amplitude signal with that of the tapping drive signal to yield the phase signal. [Reproduced from
Ph.D. thesis Rajji 2008]There are several ways to setup an AFM, but the scheme shown in Figure 1.2 is a commonly usedone. There are several methods of cantilever deflection detection (optically: with quadrantdetectors or interferometry, or mechanically using bimetals, to name a few), and there are severalways of controlling the motion of tip relative to sample (the piezo elements or other actuators canbe in the piezo tube attached to the cantilever, or they can be in the sample stage), but the generalworking principle remains the same.
[1.2.1.1] Atomic force microscopyThe working principles of AFM are very simple. An atomically sharp tip is scanned over a surfacewith feedback mechanisms that enable the piezo-electric scanners to maintain the tip at a constantforce (to obtain height information), or height (to obtain force information) above the samplesurface. Tips are typically made up of Si3N4 or Si, and extended down from the end of a cantilever.The nanoscope AFM head employs an optical detection system in which the tip is attached to theunderside of a reflective cantilever. A diode laser is focused onto the back of a reflective cantilever.As the tip scans the surface of the sample, moving up and down with the contour of the surface, thelaser beam is deflected off the attached cantilever into a dual element photodiode. Thephotodetector measures the difference in light intensities between the upper and lowerphotodetectors, and then converts into voltage. Feedback from the photodiode difference signal,through software control from the computer, enables the tip to maintain either a constant force orconstant height above the sample. In the constant force mode the piezo-electric transducermonitors real time height deviation. In the constant height mode the deflection force on the sampleis recorded. The latter mode of operation requires calibration parameters of the scanning tip to beinserted in the sensitivity of the AFM head during force calibration of the microscope.
[1.2.1.2] Mode of operation
Contact modeIn contact mode atomic force microscopy (CM-AFM), the tip scans the sample in close contact withthe surface, and the force between the tip and the surface kept constant during scanning bymaintaining a constant deflection.  This is the simplest mode used in the force microscope. Therepulsive force on the tip is a mean value of 10 ⁹ˉN.  This force is set by pushing the cantileveragainst the sample surface with a piezoelectric positioning element. In contact mode AFM the
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deflection of the cantilever is sensed and compared in a DC feedback amplifier to some desiredvalue of deflection. The tip is effectively ‘dragged along’ the sample while the feedback loop keepsthe interaction force constant by maintaining the deflection at a setpoint value. If the measureddeflection is different from the desired value the feedback amplifier applies a voltage to the piezo toraise or lower the sample relative to the cantilever to restore the desired value of deflection. Thevoltage that the feedback amplifier applies to the piezo is a measure of the height of features on thesample surface. It is displayed as a function of the lateral position of the sample. This mode allowsfor very high lateral resolution on periodic samples with low corrugation, but is typically toodamaging for protein aggregates.
Non-contact modeIn non-contact mode atomic force microscopy (NCM-AFM), the tip of the cantilever does not comein contact with the sample surface.  This is an important development in imaging that introduced asystem for implementing the non-contact mode which is used in situations where tip contact mightalter the sample in delicate ways. In this mode the tip floats 5-15 nm above the sample surface(Figure 1.3). Attractive Van der Waals forces acting between the tip and the sample are detected,and topographic images are constructed by scanning the tip above the surface. The attractive forcesfrom the sample are substantially weaker than the forces used by contact mode. Therefore the tipmust be given a small oscillation so that AC detection methods can be used to detect the smallforces between the tip and the sample by measuring the change in amplitude, phase, or frequencyof the oscillating cantilever in response to force gradients from the sample. For highest resolution, itis necessary to measure force gradients from Van der Waals forces which may extend only ananometer from the sample surface.  Measuring the tip to sample distance at each (x, y) data pointallows the scanning software to construct a topographic image of the sample surface.
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Figure 1.3: Non-contact mode atomic force microscope.
Figure 1.3 showing the scheme for dynamic mode of operation (both frequency and amplitude) innon contact mode. In frequency modulation, information about the tip sample interaction can beobserved by monitoring the change in oscillation frequency. In amplitude modulation, feedbacksignal for the image can be observed by the monitoring change in the oscillation amplitude orphase. Non contact mode is good for the scanning of soft material in both liquid and air surface,whereas contact mode results into the degradation and damage of material by penetrating thesurface in liquid medium.
Tapping modeIn tapping mode atomic force microscopy (TM-AFM), the cantilever oscillates at or near itsresonance frequency. Feedback can be performed on the measured tapping amplitude or frequency[Garcia and Perez, 2002; Higgins et al., 2005], giving rise to the terms amplitude modulated AFMand frequency modulated AFM respectively. The intermittent tip-sample contact reduces lateralforces being exerted on the sample. The resonance frequency fres is typically in the 100 kHz rangein air, and in the 30 kHz range in liquid, and tapping amplitudes range from several nm in liquid to100’s of nm in air. The minimum tapping amplitude that is necessary in air depends on the forceneeded to escape the thin water layer due to air humidity that is present on any surface exposed toair.
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TM-AFM enables imaging of soft biological samples with minimal damage. This allows oneto measure protein aggregate dimensions and material properties in a state as close as possible tothe native state. In liquid, high frequency tapping may lead to apparent stiffening of soft biologicalsamples, reducing tip induced damage even further on cells [Putman et al., 1994b].TM-AFM mode is the most commonly used for imaging amyloid fibrils, and the amplitude ofthe tapping is one important factor that determines the extent of tip and sample wear. A secondcritical parameter is the setpoint ratio (s = Aset/Afree): the ratio of the tapping amplitude setpoint (towhich the feedback loop regulates the measured amplitude, see Figure 1.2), to the tappingamplitude when the cantilever is suspended free in air or water.Because both attractive and repulsive forces act on the cantilever, and because they dependon the tip-sample separation in a nonlinear way, two stable oscillation states coexist in amplitudemodulated AFM [reviewed in Garcia and Perez, 2002]. The equation of motion for the cantilever hastwo solutions: a high and a low amplitude branch. This means that a given setpoint tappingamplitude can be achieved at two distinct tip-sample separations. If the driving amplitude is largeenough, both branches will merge into one, and only one stable solution to the equation of motionwill exist [Garcia and Perez, 2002]. For low driving amplitudes however, the AFM operator shouldbe aware that branch hopping (and related height artifacts) may occur. It is useful to qualitativelydefine tapping regimes. If s is lower than 30 %, we consider the tapping ‘hard’, if s > 70%, tapping is‘soft’. In tapping mode experiments on TTR105−115 fibrils in air, [Mesquida et al., 2007] found thatfibrils were not damaged by setpoint ratios between 10-80 %. This indicates the range of setpointratios used in amyloid research: the appropriateness of ‘hard’ or ‘soft’ tapping depends on thesample and the probe utilized.
[1.2.1.3] AFM as an imaging deviceThe atomic force microscope (AFM) is a representative example of instruments known as scanningprobe microscope. Scanning probe microscope works by monitorning the value of a physicalvariable that depends on the distance between the surface to image and a specific probe. Thetopography of the surface is then reconstructed in three-dimensional detail. The prototypescanning probe microscope was the scanning tunneling microscope (STM), in which the probe is amicroscopic electrode and the physical variable is the current between the electrode and aconductive surface on which the sample is placed. The tunneling current, varying exponentially andvery steeply with distance, is a sensible probe of surface topography. AFM instead works using
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probe displacement as the variable, being similar conceptually to a miniature phonograph. Theprobe itself is a solid, sharp microscopic tip located at the end of a flexible cantilever.The tip and the surface are put in contact or close proximity, and the cantilever deflectiondue to the tip sample interactions is the variable being monitored. The cantilever, normally, can bemodeled as a simple Hookean spring and therefore its response is linear with applied force. In mostcases, cantilever deflection is in turn probed and amplified by a laser beam that reflects on thecantilever very end, forming a so-called optical lever system. The laser beam reflected by the tiphits a photodiode, which records the displacement of the laser beam from a reference point. Thesystem in this way achieves a resolution of the order of the nanometer.A piezoelectric scanner is usually used to move the sample (or the tip) in three dimensions,allowing the tip to scan various portions of the sample. Piezoelectric scanners allow AFMs to reach1 nm of lateral resolution. Atomic resolution has been reached vertically for hard materials invacuum conditions. On the other hand, AFM can easily be applied to biological samples because itrequires little or no sample preparation and works readily in physiological conditions (liquidbuffer, room temperature etc.). Live eukaryotic cells can be extensively analyzed with the AFM[Mathur et al., 2001].
[1.2.1.4] Imaging conditionsAFM on biomaterials can be performed in air or in a liquid, such as an aqueous pH-bufferingsolution.
Imaging in airThe main advantages of imaging in air are, (i) that sample preparation is easier, sample no need toput in liquid, and (ii) the sample can be used for long time after preparation without degradation. Adisadvantage of AFM in air compared to in liquid is that a tapping amplitude in the order of 100 nmis required (with associated high tapping force) to overcome the strong capillary force that is due toa thin water layer that tends to form on the substrate surface.
Imaging in liquidOne undeniable reason for imaging in liquid is that in liquid environment physiological conditionsresembles much more close to the proteins and other biological systems. Also, in an aqueousenvironment it is possible to study biomolecular interactions.
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In the case of amyloid fibrils, a disadvantage of imaging in liquid is their higher fragility inliquid than in air. Also, it is sometimes hard to bind the sample to the substrate (although thatseems to be more of a problem for DNA than for protein aggregates). Another disadvantage is thatthe samples cannot be kept for the next use, since the evaporation of the water droplet leads tobuffer salt deposition, while continued immersion in a large quantity of buffer would presumablylead to desorption of the aggregates. A major application for AFM imaging in buffer is thataggregations can be monitored in real-time through in situ imaging: when the buffer containsmonomers of the protein of interest and the buffer conditions are right, surface templatedaggregation may occur [Hoyer et al., 2004]. Also, the directionality of fibril growth becomesaccessible [Blackley et al., 2000; Goldsbury et al., 1999; Zhu et al., 2002].
[1.2.1.5] Choice of probe and substrateAn AFM probe consists of a cantilever with a tip, and its properties are critical to the results of theimaging of biomolecular samples. The lateral resolution of AFM images depends on the sharpnessof the tip that is used, and the cantilever stiffness and resonance frequency determine the forceexerted on the sample, and any resulting damage.The substrate used for imaging of amyloid fibrils is a relevant factor in in-situ aggregationstudies: the fibrils may form a pattern based on the atomic structure of the substrate [Yang et al.,2002]. The properties of the surface on which the sample is deposited also influence the kineticsand morphology of amyloid fibril formation. In an in-situ TM-AFM study in liquid, the morphologyof Aβ aggregates was different on hydrophilic mica than on hydrophobic graphite: on mica,particulate aggregates formed, whereas on graphite, linear assemblies similar to protofilamentsformed [Kowalewski and Holtzman, 1999]. This dependence of fibril morphology on substratehydrophobicity implies that fibril formation may be expedited on interfaces between aqueoussolutions and lipid surfaces, as would occur at cellular membranes and lipoprotein particles in aliving cell. Aβ1−42 early aggregates deposit with a higher yield on hydrophilic mica than onhydrophobic graphite, and the opposite is true for mature fibrils [Arimon et al., 2005]. Finally,hydrophobic surface favor the formation of surface nanobubbles [Yang et al., 2007], which isundesirable when imaging proteins. For AFM imaging of protein fibrils, freshly cleaved micaappears to be the most convenient substrate.
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[1.2.1.6] Force spectroscopyIn addition to these topographic measurements, the AFM can also provide much more informationabout the molecular motion behavior and fluctuation of the single molecule (both biological andnon-biological) at nano-scale. The AFM can also record the amount of force felt by the cantilever asthe probe tip is brought close to and even indented into a sample surface and then pulled away.This technique can be used to measure the long range attractive or repulsive forces between theprobe tip and the sample surface, elucidating local chemical and mechanical properties likeadhesion and elasticity, and even thickness of adsorbed molecular layers or bond rupture lengths.Force curves (force-vs-distance curve) typically show the deflection of the free end of theAFM cantilever as the fixed end of the cantilever is brought vertically towards and then away fromthe sample surface. Experimentally, this is done by applying a triangle-wave voltage pattern to theelectrodes for the z-axis scanner. This causes the scanner to expand and then contract in thevertical direction, generating relative motion between the cantilever and sample. The deflection ofthe free end of the cantilever is measured and plotted at many points as the z-axis scanner extendsthe cantilever towards the surface and then retracts it again. By controlling the amplitude andfrequency of the triangle-wave voltage pattern, the researcher can vary the distance and speed thatthe AFM cantilever tip travels during the force measurement.Similar measurements can be made with oscillating probe systems like Tapping Mode andnon-contact AFM. This sort of work is just beginning for oscillating probe systems, butmeasurements of cantilever amplitude and/or phase versus separation can provide moreinformation about the details of magnetic and electric fields over surfaces and also provideinformation about viscoelastic properties of sample surfaces.
[1.2.1.7] Anatomy of a force curve
A: In this region cantilever does not touch the surface, if the cantilever feels a long-range attractive(or repulsive) force it will deflect downwards (or upwards) before making contact with the surface.
B: As the probe tip is brought very close to the surface, it may jump into contact if it feels sufficientattractive force from the sample.
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Figure 1.4: A typical AFM force curve.
C: Once the tip is in contact with the surface, cantilever deflection will increase as the fixed end ofthe cantilever is brought closer to the sample. If the cantilever is sufficiently stiff, the probe tip mayindent into the surface at this point. In this case, the slope or shape of the contact part of the forcecurve can provide information about the elasticity of the sample surface.
D: After loading the cantilever to a desired force value, the process is reversed. As the cantilever iswithdrawn, adhesion or bonds formed during contact with the surface may cause the cantilever toadhere to the sample some distance past the initial contact point on the approach curve (B).A key measurement of the AFM force curve is the point at which the adhesion is broken andthe cantilever comes free from the surface. This can be used to measure the rupture force requiredto break the bond or adhesion.
[1.2.1.8] AFM calibrationThe cantilever elastic constant needs to be measured for each experiment: this is due tounavoidable inhomogeneities in the batches of commercial cantilevers. This is usually done day today by the “thermal tune” method that is by measuring the thermal oscillation spectrum of the freecantilever (not in touch with any surface) and using the equipartition theorem to obtain the actualelastic constant. The cantilever is here treated as a simple oscillator and the Brownian motion of themain fundamental oscillation mode of the cantilever gives the elastic constant by the simpleformula:
(2.1)
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where the Boltzmann constant, T is is temperature and is the square mean cantileverdeflection.
This latter variable is found by fitting the power spectrum of the cantilever thermal noise, with theadvantage of avoiding interference from both non-thermal oscillation at other discrete frequenciesand white noise.In practice, it must be noticed that today more complex, empirical equations are used, tocorrect significant deviations from the ideal oscillator behaviour of the cantilever. The typical erroris ±20% [Hutter et al., 1993; Florin et al., 1995]. The other essential parameter to be known is theoptical lever sensitivity, i.e. the ratio between cantilever deflection and the photodiod outputvoltage difference. This depends from the optical properties of the cantilever, the medium (air orwater), the eventually present fluid cell etc. and also needs to be measured for each cantilever. Thisis usually done by pressing the cantilever on a hard surface (i.e. glass or mica) at high forces:assuming that no substrate deformations happen, the cantilever deflection must be theoricallyequal to the piezo movement and the ratio can be calculated. When this is done, the sample can beput in place under the tip. There are a number of free parameters that the experimenter mustdecide before starting the experiment (most of them can also be changed during operation): thespeed, the length range, the maximum force acting on contact on the surface, the scan rate (numberof points recorded per second) are usually the most important.
[1.2.1.9] AFM vs other imaging technique
AFM vs STMIt is an interesting to compare AFM and its precursor Scanning Tunneling Microscope. In somecases, the resolution of STM is better than AFM because of the exponential dependence of thetunneling current on distance. The force-distance dependence in AFM is much more complex whencharacteristics such as tip shape and contact force are considered. STM is generally applicable onlyto conducting samples while AFM is applied to both conductors and insulators. In terms ofversatility, needless to say, the AFM wins. Furthermore, the AFM offers the advantage that thewriting voltage and tip-to-substrate spacing can be controlled independently, whereas with STMthe two parameters are integrally linked.
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AFM vs SEMCompared with Scanning Electron Microscope, AFM provides extraordinary topographic contrastdirect height measurements and unobscured views of surface features (no coating is necessary).
AFM vs TEMCompared with Transmission Electron Microscopes, three dimensional AFM images are obtainedwithout expensive sample preparation and yield far more complete information than the twodimensional profiles available from cross-sectioned samples.
AFM vs Optical microscopeCompared with Optical Interferometric Microscope (optical profiles), the AFM providesunambiguous measurement of step heights, independent of reflectivity differences betweenmaterials.
[1.2.2] Fluorescence polarizationFluorescence Polarization (FP) was first described by Perrin in 1926. When a small fluorescentmolecule is excited with plane-polarized light, the emitted light is largely depolarized becausemolecules tumble rapidly in solution during their fluorescence lifetime (the time betweenexcitation and emission). It is a powerful tool to study molecular interactions (protein-protein,protein-DNA and protein-ligands) by monitoring changes in the apparent size of fluorescently-labeled or inherently fluorescent molecules.
Principle behind fluorescence polarizationWhen a fluorescent molecule is excited with plane polarized light, light is emitted in the samepolarized plane, provided that the molecule remains stationary throughout the excited state (whichhas duration of 4 nanoseconds for fluorescein). If the molecule rotates and tumbles out of this planeduring the excited state, light is emitted in a different plane from the excitation light. If verticallypolarized light is exciting the fluorophore, the intensity of the emitted light can be monitored invertical and horizontal planes (degree of movement of emission intensity from vertical tohorizontal plane is related to the mobility of the fluorescently labeled molecule (see Figure 1.4)). Ifa molecule is very large, little movement occurs during excitation and the emitted light remainshighly polarized. If a molecule is small, rotation and tumbling is faster and the emitted light isdepolarized relative to the excitation plane.
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Figure 1.5: Scheme showing polarization of plane polarized light by fluorescent molecule in fluorescent
polarization experiment.Polarization is defined as a function of the observed parallel ( ) and perpendicular intensities ( ):
(2.2)
If the emission is completely polarized in the parallel direction, i.e., the electric vector of theexciting light is totally maintained, then:
(2.3)
If the emitted light is totally polarized in the perpendicular direction then:
(2.4)
The limits of polarization are thus +1 to -1
Another term frequently used in the context of polarization is anisotropy (usually designated aseither A or r) which is defined as:
(2.5)
By analogy to polarization, the limits of anisotropy are +1 to -0.5
We can write
- 21 -
(2.6)Or (2.7)
For example
P r0.50 0.400.30 0.220.10 0.069
Clearly, the information content in the polarization function and the anisotropy function is identicaland the use of one term or the other is dictated by practical consideration.Small molecules rotate quickly during the excited state, and upon emission, have lowpolarization values. Large molecules, caused by binding of a second molecule, rotate little duringthe excited state, and therefore have high polarization values.
Dependence of fluorescence polarization on molecular mobilityInterpretation of the dependence of the fluorescence polarization on molecular mobility is usuallybased on a model derived in 1926 from the physical theory of Brownian motion by Perrin:
(2.8)
Where is the fundamental polarization of the dye (for fluorescein, rhodamine and BODIPY dyes,is close to the theoretical maximum of 0.5), r is the excited-state lifetime of the dye and is therotational correlation time of the dye or dye conjugate. These relationships can be expressed interms of fluorescence anisotropy in an equivalent and mathematically simpler manner. For ahydrodynamic sphere, can be estimated as follows:
(2.9)
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Where η = solvent viscosity, T = temperature, R = gas constant and V = molecular volume of thefluorescent dye or dye conjugate. In turn, V can be estimated from the molecular weight of the dyeor dye conjugate with appropriate adjustments for hydration.
PolarizerThe most common polarizers used today are (i) dichroic devices, which operate by effectivelyabsorbing one plane of polarization (e.g. Polaroid type-H sheets based on stretched polyvinylalcohol impregnated with iodine) and (ii) double refracting calcite (CaCO3) crystal polarizerswhich differentially disperse the two planes of polarization (examples of this class of polarizers areNicol polarizers, Wollaston prisms and Glan-type polarizers such as the Glan-Foucault, Glan-Thompson and Glan-Taylor polarizers).
[1.3] α-Synuclein
[1.3.1] Historical overviewThe name ‘Synuclein’ was first derived from the protein that was found in both synapses and in the
nuclear envelope [Maroteaux et al., 1988]. The 143-amino acid (aa) long neurone-specific proteinwas isolated from the electric organ of the fish Torpedo californica by expression screening wascalled synuclein. Independently, NACP, the 140-aa non-Aβ component of AD amyloid precursor[Ueda et al., 1993], and synelfin [George et al., 1995] were cloned in human and in the zebra finch,respectively. They were found to be orthologs of torpedo fish synuclein and rat brain synuclein[Campion et al., 1995; Maroteaux et al., 1991; Jakes et al., 1994]. When Jakes et al. cloned β-synuclein as a second member of the human synuclein family, they termed the initially isolatedfamily members ‘α-synuclein.’ All α-synucleins were shown to be extremely well conserved amongdistantly related species [George et al., 1995; Maroteaux et al., 1991; Jakes et al., 1994]. α-Synucleinwas not found in the nucleus in several subsequent studies. It appears therefore to be a purelypresynaptic protein [Jakes et al., 1994; Iwai et al., 1995].
[1.3.2] The Synuclein familyThree members of the human synuclein family have been identified: α-, β-, and γ-synuclein (see
Figure 1.6). The genes are located on chromosome 4q21 [Shibasaki et al., 1995; Spillantini et al.,1995; campion et al., 1995 and Chen et al., 1995], 5q35 [Spillantini et al., 1995], and 10q23[Lavedan et al., 1998], respectively.
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(i) α-Synuclein (NACP)
(ii) β-Synuclein (PNP14)
(iii) γ-Synuclein (BCSG1)
Figure 1.6: The human synuclein family. The different synucleins are represented as a bar. Amino acid
positions are indicated at the bottom. The N-terminal amphipathic region, the hydrophobic NAC region, and the
acidic tail are separated by vertical dashed lines and are differently hatched. The α-112 splice variants of α-
synuclein (lacking 28 amino acids within the acidic tail) as well as β- and γ-synuclein are shown. The NAC region
of β-synuclein lacks 11 central amino acids (residues 73–83). The degree of amino acid identity compared to α-
synuclein, according to cross-species consensus sequences [Clayton et al., 1998], and is given as a percentage
below each domain. [Reproduced from Lucking et al., 2000]
β- and γ-SynucleinsThree different types of synucleins (α, β-and γ-synuclein) have been identified. β-and γ-synucleinare 78% and 60% identical to α-synuclein. They preserve some characteristic features of α-synuclein, while missing others. The α- and β-synucleins share a conserved C-terminus with threeidentically placed tyrosine residues. However, β-synuclein lacks 11 residues within the specific NACregion [Clayton and George, 1998]. γ- Synuclein specifically lacks the tyrosine rich C-terminalsignature of α- and β-synucleins [Clayton and George, 1998]. Comparison of the structuralproperties of the members of synuclein family by several physicochemical methods revealed thatall three synuclein are typical natively unfolded proteins, with some structural differences. β-Synuclein exhibited the properties of a typical random coil, whereas α- and γ-synucleins wereslightly more compact and structured [Uversky et al., 2002d]. Both α- and γ-synucleins were shown
- 24 -
to form fibrils, whereas β-synuclein did not fibrillate when incubated under the same conditions[Uversky et al., 2002d]. However, even apparently ‘nonamyloidogenic’ β-synuclein can be forced tofibrillate in the presence of some metals (Zn²⁺, Pb²⁺, and Cu²⁺ ions) or pesticides [Yamin et al.,2005]. Furthermore, the metal-induced fibrillation of β-synuclein was further accelerated by theaddition of GAGs or high concentrations of macromolecular crowding agents [Yamin et al., 2005].Intriguingly, the addition of either β- or γ-synuclein in a 1 : 1 molar ratio to α-synuclein solutionsubstantially increased the duration of the lag-time and dramatically reduced the elongation rate of
α-synuclein fibrillation [Uversky et al., 2002d]. Fibrillation was completely inhibited at a 4 : 1 molarexcess of β- or γ-synuclein over α-synuclein [Uversky et al., 2002d]. β-Synuclein inhibited α-synuclein aggregation in animal models too [Hashimoto et al., 2001]. This suggests that β- and γ-synucleins may act as regulators of α-synuclein fibrillation in vivo, potentially acting as chaperones[Uversky et al., 2002d].
[1.3.3] Structural and conformational aspects of α-SynucleinStructural and conformational behavior of α-synuclein is crucial to understand the aggregation andfibrilization process α-synuclein. α-Synucleins from different organisms possess a high degree ofsequence conservation [Clayton and George, 1998]. α-Synuclein-140 is the best isoform reportedout of all three synucleins [Bayer, 2006], which is the whole and major transcript of the protein.Two other isoforms, α-synuclein-126 and α-synuclein-112, are produced by alternative splicing,resulting in an inframe deletion of exons 3 and 5, respectively. Exon 3 encodes for residues towardsthe N-terminus, residues 41–54, and exon 5 encodes for residues towards the C-terminus, residues103–130.On the basis of structural point of view α-synuclein-140 can be divided into three regions:(i) The N-terminal region, residues 1–60, include the sites of three familial PD mutations andcontain four 11-amino acid, imperfect repeats with a highly conserved hexameric motif (KTKEGV).The N-terminal region is predicted to form amphipathic α-helices, typical of the lipid-bindingdomain of apolipoproteins [George et al., 1995; Clayton and George, 1998]. (ii) The central region,residues 61–95, comprises the highly aggregation-prone NAC sequence [Ueda et al., 1993; Han etal., 1995]. (iii) The C-terminal region, residues 96–140, is highly enriched in acidic residues andprolines. Three highly conserved tyrosine residues, which are considered a signature of the α- andβ-synuclein family, are located in this region.
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Figure 1.7: Schematic representation of primary structure of α-synuclein.
[1.3.3.1] α-Synuclein as an intrinsically disordered protein
α-Synuclein is a typical intrinsically disordered (or natively unfolded) protein, which possessesdisordered structure under physiological conditions in vitro [Weinreb et al., 1996; Uversky et al.,2001a]. Intrinsically disordered proteins have recently been recognized as a new protein class,which are gaining considerable attention due to the capability of these proteins to performnumerous biological functions despite the lack of unique structure [Uversky et al., 2000, 2005a;Uversky, 2002a, b, 2003; Fink, 2005]. These proteins exist as dynamic and highly flexible ensemblesthat undergo a number of distinct interconversions on different time scales. The difference in aminoacid composition between ordered and intrinsically disordered proteins created the basis for thedevelopment of numerous algorithms that predict disordered proteins or regions.According to PONDR VL3 [Li et al., 1999; Romero et al., 2001], VSL2 [Obradovic et al., 2005],RONN [Yang et al., 2005], and IUPred [Dosztanyi et al., 2005] revealed that this protein is predictedto be almost completely disordered and its sequence is typical of intrinsically disordered proteins.In agreement with these computational predictions, α-synuclein was shown to possess littleordered structure under physiological conditions by techniques as far-UV circular dichroism andFourier transform infra red spectroscopy, sedimentation, gel-filtration, dynamic light scattering,and SAXS [Weinreb et al., 1996; Eliezer et al., 2001; Uversky et al., 2001a; Uversky, 2003]. A high-resolution NMR analysis revealed that α-synuclein is largely unfolded in a solution, but exhibits aregion between residues 6 and 37 with a preference for helical conformation [Eliezer et al., 2001].Raman optical activity spectroscopy has revealed that α-synuclein may contain some residues in ahelical poly-(L-proline) II-like conformation [Syme et al., 2002].
[1.3.3.2] Conformational equilibria in α-synucleinThe conformational behavior of α-synuclein under a variety of conditions was extensively analyzed[Uversky, 2003]. This analysis found that the structure of α-synuclein is extremely sensitive to itsenvironment and can be easily modulated by a change in conditions. The list of known α-synucleinconformations includes:
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(i) The extended state is the intrinsic state of α-synuclein under physiologic conditions in vitro[Weinreb et al., 1996; Uversky et al., 2001a; Sandal et al., 2008] and in vivo [McNulty et al., 2006].(ii) The pre-molten globule state is the predominant state of α-synuclein in conditions like a low pH[Uversky et al., 2001a], a high temperature [Uversky et al., 2001a], low concentrations of organicsolvents [Munishkina et al., 2003] and trimethylamine N-oxide [Uversky et al., 2001d], variousmetal ions [Uversky et al., 2001b], various salts [Munishkina et al., 2004], several commonpesticides/herbicides [Uversky et al., 2001c, 2002a; Manning-Bog et al., 2002], heparin and otherglycosoaminoglycans [Cohlberg et al., 2002], some polycations [Goers et al., 2003a].(iii) The α-helical membrane bound form: interaction of α-synuclein with synthetic vesiclescontaining acidic phospholipids is accompanied by a dramatic increase in α-helical content[Davidson et al., 1998; Perrin et al., 2000]. For example, upon addition of small unilamellar vesiclescontaining 30% phosphatidylserine and 70% phosphatidylcholine, the circular dichroism spectrumof purified α-synuclein shifts from a characteristic random coil pattern with a 195 nm minimum toa typical α-helical pattern with 206 and 222 nm minima [Chandra et al., 2003]. Using NMR, thesedramatic changes were attributed to the formation of α-helical conformation in the N-terminalfragment (~100 residues) [Chandra et al., 2003]. A noticeable break in the helical pattern wasobserved around residues 43 and 44, revealing an interruption of the helical structure in this region[Chandra et al., 2003]. Later, the formation of two curved α-helices (Val3–Val37 and Lys45–Thr92)connected by a well ordered, extended linker was reported [Ulmer et al., 2005].The acidic glutamate-rich C-terminal region (Asp98–Ala140) was shown to behave as ahighly mobile tail and remained unstructured even in the presence of membranes [Jao et al., 2004;Ulmer et al., 2005]. However, it becomes insensitive to protease digestion when the micelle bound
α-synuclein is exposed to calcium [de Laureto et al., 2006]. (iv) α-helical and β-structural species inorganic solvents: The addition of various alcohols increases the content of ordered secondarystructure in α-synuclein [Munishkina et al., 2003]. The type of structural transformation induced byhigh solvent concentrations was dependent on the type of alcohol used, where simple alcoholsinduced enrichment in β-sheet and fluorinated alcohols promoted enrichment in α-helix[Munishkina et al., 2003]. Both α-helical and β-sheet species were shown to be initially monomeric,but underwent association over longer times, where β-structure rich conformations were veryprone to form amorphous aggregates [Munishkina et al., 2003]. Oligomeric α-helical globularspecies possibly possessing rigid tertiary structure were induced in α-synuclein by highconcentrations of trimethylamine N-oxide [Uversky et al., 2001d]. (v) Dimers: α-Synuclein is able toform morphologically distinct oligomers and aggregates. For example, the prolonged incubation of
- 27 -
this protein at high temperatures results in the progressive aggregation, where dimers are formedfirst [Uversky et al., 2001e]. The formation of oxidative dimers and higher-order oligomers withdityrosine cross-links under conditions of oxidative stress was also reported [Souza et al., 2000].(vi) Oligomers: In addition to covalent and non-covalent dimers, α-synuclein was shown to form aseries of morphologically different soluble oligomers. Nitrated α-synuclein assembles intooligomeric spheroids [Yamin et al., 2003a]. The incubation of α-synuclein with different metals gaverise to three different classes of oligomers: Cu²⁺, Fe³⁺, and Ni²⁺ ions yielded 0.8–4 nm sphericalparticles, similar to α-synuclein incubated without metal ions; Mg²⁺, Cd²⁺, and Zn²⁺ ions gave larger,5–8 nm spherical oligomers; and Co²⁺ and Cd²⁺ ions produced ring oligomers with diameters of 70–90 nm and 22–30 nm in the case of Co²⁺ ion [Lowe et al., 2004]. Several oligomeric ‘protofibrilar’species with various morphologies were detected by atomic force microscopy at early stages offibrillation [Conway et al., 1998, 2000c; Ding et al., 2002; Lashuel et al., 2002a, b]. The earliest formof α-synuclein protofibrils appeared to be predominantly spherical with heights varying between2.5 and 4.2 nm [Conway et al., 2000b; Ding et al., 2002]. Under the appropriate conditions, thesespherical oligomers convert into rings [Ding et al., 2002]. In addition to the complete rings, thepartially formed rings (i.e. crescents) were found [Ding et al., 2002]. The incubation of the spherical
α-synuclein oligomers with brain derived membranes was shown to also produce pore-like ring-type protofibrils [Ding et al., 2002]. (vii) Insoluble aggregates: Finally, α-synuclein was shown toassemble into large, insoluble aggregates with two distinct morphologies–amorphous aggregatesand fibrils. The type of insoluble aggregate is also determined by the solution conditions. Forexample, α-synuclein precipitated from solutions containing high concentrations of simple alcoholspredominantly form amorphous aggregates. In many other cases, the major insoluble species areamyloid-like fibrils. In a few cases, the successful partitioning between these two pathways isobserved and α-synuclein is present in both fibrillar and amorphous forms simultaneously. Thevarious studies described above indicate that α-synuclein possesses a remarkable conformationalplasticity, being able to adopt structurally unrelated conformations, including a substantiallyunfolded native state, and fibrillation prone partially folded conformation, and various α-helical andβ-sheet species folded to different degrees in both monomeric and oligomeric states [Uversky et al.,2002d; Uversky, 2003]. Furthermore, this protein can form several morphologically different typesof aggregates, including oligomers (i.e. spheres or ring), amorphous aggregates, and amyloid-likefibrils [Uversky et al., 2002d; Uversky, 2003]. The various insoluble aggregates observed in vitromight represent major building blocks of pathology-related inclusions, such as LBs, LNs, GCIs,
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neuronal cytoplasmic inclusions, and axonal spheroids, which have all been found in neuronsaffected by the synucleinopathies.
[1.3.4] α-Synuclein aggregation
[1.3.4.1] Role of partial folded structure in aggregation or fibril formationEarly stages of fibril formation involve the partial folding of α-synuclein into the highly fibrillation-prone pre-molten globule-like conformation, which represents a key intermediate on thefibrillation pathway [Uversky et al., 2001a]. Hence, factors that shift the equilibrium in favor of thispartially folded conformation facilitate fibril formation. Possibilities include point mutations thatshift the conformational equilibrium towards these partially folded conformations, non-polarmolecules such as some pesticides that might preferentially bind to them. Cations that might mimicover the amino acid residue at the effect of low pH (high proton concentration) in protein solution.Aggregation might be favored by other factors as well that result in an increase in the concentrationof α-synuclein itself or into a chemical modification of the protein (e.g. via oxidative damage, etc.).As stated above, a number of environmental factors are able to induce partial folding of α-synuclein.Consequently, it was not surprising to find that all these factors do indeed result in the accelerated
α-synuclein fibrillation [reviewed in Uversky 2003].
[1.3.4.2] Mechanism of α-synuclein aggregationBecause of its “natively unfolded” structure, α-synuclein might be especially prone to self-aggregateor to cause the aggregation of other proteins or intracellular structures (Figure 1.8). In vitro, bothfull-length WT and mutant α-synuclein (A30P and A53T) when present in supersaturatingconditions undergo time-, temperature-, pH- and concentration-dependent self-aggregation intofibrils [Hashimoto et al., 1998; Giasson et al., 1999].
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Figure 1.8: Putative pathological mechanisms of α-synuclein. The binding partners and hypothetical steps
of the different pathogenic mechanisms are indicated by arrows. PA, phosphatidic acid; PLD2, phospholipase D2;
ERK, extracellular regulated kinase; WT, wild type; A30P and A53T, described α-synuclein mutations; >, possibly
more toxic than. [Reproduced from Lucking et al., 2000]These fibrils were similar to those isolated from LBs of patients with PD and DLB, or fromthe filamentous inclusions characteristic for MSA [Conway et al., 1998]. Fibrillization wasaccompanied by a change in the secondary structure of α-synuclein from an unfolded random coilto an antiparallel β sheet [Narhi et al., 1999; Conway et al., 2000a; Conway et al., 2000b].In a similar time-, concentration-, and temperature-dependent manner, the α-synucleinfragment NAC self-aggregated into amyloid like filaments with a thioflavin-positive β-sheetstructure [Iwai et al., 1995; Han et al., 1995], residues 1–18 of the NAC peptide being sufficient forthis aggregation [El-Agnaf et al., 1998]. Solutions containing aggregated α-synuclein, NAC (1–35)and NAC (1–18) were toxic to SH-SY5Y cells in vitro [El-Agnaf et al., 1998]. Fibril formation fromwild-type and mutated (A53T and A30P) α-synuclein involves nucleation-dependent elongation[Conway et al., 2000; Wood et al., 1999] in which the protein aggregates into seeds and thenaccelerates fibril formation in a dose-dependent manner. Heterologous seeding of wild-type α-synuclein by A53T-mutated seeds also occurred, a possible explanation for the dominant effect ofthis mutation.
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Although, it is clear that two mutations (A30P and A53T) in the α-synuclein gene can giverise to an inherited form of PD, the mechanism by which the disease occurs is not very clear. Onepossibility is that α-synuclein containing these mutations aggregates more rapidly, and indeed,both α-synuclein mutations appear to accelerate the aggregation process [Conway et al., 1998; El-Agnaf et al., 1998a; Giasson et al., 1999; Narhi et al., 1999]. Aggregates formed from wild-type α-synuclein or from either mutant were thioflavin-S positive, indicative of the presence of aggregateswith the β-pleated sheet conformation characteristic of amyloid fibrils [Hashimoto et al., 1998; El-Agnaf et al., 1998a]. Anti-parallel β-sheet structure in wild-type and mutant aggregates has beenconfirmed by Fourier transform infrared spectroscopy [Narhi et al., 1999].More recently, the kinetic mechanism of α-synuclein aggregation was studied and found tobe rate limited by a nucleation step. Addition of preformed fibrils of α-synuclein caused rapidaggregation of a supersaturated solution, bypassing a lag phase that occurred in the absence ofseeding. Aggregate growth followed first-order kinetics with respect to α-synuclein concentration,and α-synuclein (A53T) could seed the aggregation of wild-type α-synuclein. In addition, the wild-type and mutant forms of α-synuclein had similar critical concentrations, as measured by peptideremaining in solution after complete aggregation and attainment of equilibrium between peptide insolution and peptide in fibrillar form. These results suggest that the more rapid rate of aggregationof A53T α-synuclein compared to wild-type could not be explained by decreased solubility but wasdue to an increased nucleation rate [Wood et al., 1999]. Differences in the morphology of fibrilsformed by wild-type and mutant α-synucleins under the same conditions have been reported [El-Agnaf et al., 1998a; Giasson et al., 1999].Goedert and co-workers carried out studies on fibril morphology and staining pattern usingantisera of different regional specificity in immunoelectron microscopy of filamentous assembliesisolated from the Sarcosyl-insoluble fraction of brains from patients with PD and dementia withLewy bodies. They observed 5- and 10-nm filaments and a staining pattern that could be explainedby postulating a buried N-terminus of all α-synuclein molecules except the one at the end of eachfilament; in other words, fibrils were polar structures. They proposed a model in which the α-synuclein molecules in Lewy bodies and Lewy neuritis assembled first to form protofibrils, two ofwhich could associate to produce a variable twisted mature fibril [Spillantini et al., 1998a].
[1.3.4.3] Aggregation of α-synuclein fragmentsThe discovery of NAC, a hydrophobic peptide that was the second major component in Alzheimer’sdisease amyloid, led to the suggestion that it might seed amyloid formation in plaques [Ueda et al.,
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1993]. Subsequently NAC fragment (amino acid residues 61-95) was found to aggregate in vitro.These aggregates have been shown, by thioflavin-S staining, Congo red staining, and Fouriertransform infrared spectroscopy, to contain β-sheet structure, indicative of the presence ofamyloid-like fibrils. Indeed, the aggregates had distinct fibrillar morphology, as observed byelectron microscopy of negatively stained samples. Electron microscopy has revealed the presenceof clumps of short irregular fibrils of variable length, mainly of 4–11 nm in diameter, similar in sizeto those found in neuritic plaques [El-Agnaf et al., 1998b, c; Han et al., 1995; Iwai et al., 1995b]. Thetransition from totally random structure to predominantly β-sheet like structure upon ageing ofNAC in solution may be a general prelude to the formation of toxic fibrils by amyloidogenic peptides[El-Agnaf et al., 1998b, c].
Figure 1.9: Comparison of NAC with Aβ, PrP, and IAPP sequences. The GAVV sequence in NAC and GAXX
sequences in the amyloidogenic regions of three other proteins are shaded. This alignment highlights a number
of sequence identities between any pair of the four peptides (underlined). [Reproduced from El-Agnaf et al.,
1998c] Examination of the N-terminal sequence of NAC revealed a degree of similarity to regionscrucial for the aggregation and toxicity of three other amyloidogenic proteins; namely, Aβ, prionprotein, and islet amyloid polypeptide (see Figure 1.9). A four-residue motif, Gly-Ala-X-X, where Xis an amino acid with an aliphatic side chain, that is common to all four peptides is shaded darkgrey. The physicochemical characteristics of these sequences determine the similar fibrillogenictendencies of NAC, islet amyloid polypeptide, Aβ, and prion protein, so that the amyloidogenicregion of NAC lie in its N-terminal half [El-Agnaf et al., 1998c].
[1.3.4.4] α-Synuclein mutantsThe term mutation stands for the change in genomic sequence and that changes leads to thedifferent results compared to the parental sequence. There are several mutations in α-synucleinsequence have been reported, but only three mutations (A30P, E46K, and A53T) are leads to theformation of familial parkinson’s disease; the A53T mutation in a large Italian-American family,
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known as the Contursi kindred [Polymeropoulos et al., 1997]; the A30P mutation in a Germanfamily [Kruger et al., 1998]; and the E46K mutation in a Spanish family with autosomal dominantparkinsonism, dementia, and visual hallucinations of variable severity [Zarranz et al., 2004].Despite of point mutations in α-synuclein genes, we have prepared cystein mutated dimerfor the study of α-synuclein aggregation. The cystein mutated dimer is different from the pointmutated α-synuclein. Our idea was to understand the aggregation mechanism of α-synuclein andthe arrangement of monomeric α-synuclein in beta sheet like structure during aggregation process,by studying cystein mutated α-synuclein dimer.
[1.3.4.5] Seeded growth of α-synuclein
α-Synuclein is a major filamentous constituent of Lewy bodies, a pathological hallmark ofParkinson’s disease (PD) [Spillantini et al., 1997; Spillantini et al., 1998]. When incubated in vitro, α-synuclein has undergone structural alteration from its natively unfolded state to cross β-sheetconformation, which results in the filamentous aggregate formation. The filamentous aggregateformation of α-synuclein has been considered to be a nucleation dependent process [Wood et al.,1999]. It could be seeded by a previously self-assembled species of α-synuclein acting as a nucleus.Its growth kinetics, therefore, is dependent upon the seed concentration, whereas a criticalconcentration of the α-synuclein monomer at the stationary phase is independent of the seed[Wood et al., 1999]. During fibril formation, natively unfolded α-synuclein is believed to adopt apartially unfolded intermediate structure and transform into highly ordered fibrils. Underoptimized conditions of pH and temperature for this partially unfolded intermediate, the α-synuclein fibril formation could be accelerated [Uversky et al., 2001]. Macromolecular crowding,metal ions, and small chemicals also facilitated the fibril formation [Munishkina et al., 2004;Uversky et al., 2001; Uversky et al., 2001b]. Some chemicals, however, induced α-synuclein toprotofibrils instead of the eventual fibril formation [Lee et al., 2006].
[1.3.4.6] Factors affecting α-synuclein aggregationThere are more than hundred factors and thousand compounds have been found to affect α-synuclein aggregation in vitro including metal ions, pesticides, herbicides, detergents, drugs,chemicals and particularly proteins like chaperones [reviewed in Uversky 2007].
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[1.3.4.7] Proteins inhibiting α-synuclein aggregation
ChaperonesThere are some heat shock proteins which have been found to slow down the α-synucleinaggregation. These proteins belong to the family of chaperone proteins. These proteins suppressprotein aggregation and participate in protein refolding and/or degradation. Several chaperones,including torsin A, a protein with homology to yeast heat shock protein 104 [Walker et al., 2001],αB-crystallin, a small chaperone that binds to unfolded proteins and inhibits aggregation, molecularchaperones Hsp70 and Hsp40, and several other heat shock proteins [McLean et al., 2002], beingprominent components of LBs and/or GCIs, co-localize with α-synuclein. The over-expression oftorsin A and heat shock proteins suppressed α-synuclein aggregation in a cellular model [McLean etal., 2002]. In vitro analysis revealed that αB-crystallin serves as a potent inhibitor of wild-type,A30P and A53T α-synucleins fibrillation [Rekas et al., 2004]. Directed expression of the molecularchaperone Hsp70 prevented dopaminergic neuronal loss associated with α-synuclein in Drosophila,whereas the interference with endogenous chaperone activity accelerated α-synuclein toxicity.These informations suggest a role for chaperones in pathologies involving α-synuclein in humans,such that they may be a critical part of the neuronal arsenal that mitigates α-synuclein toxicity.
[1.3.5] α-Synuclein and neurodegenerative diseaseOut of the three synucleins, only α-synuclein is associated with the filamentous inclusions of Lewybody diseases and MSA. Using specific antibodies, β- and γ-synuclein have been shown to be absentfrom these inclusions [Spillantini et al., 1997; Spillantini et al., 1998]. In addition, there is no geneticevidence linking the β- and γ-synuclein genes to disease. In the context of inherited PD, theimmediate question is how missense mutations in the repeat region of the α-synuclein gene cancause degeneration of dopamine nerve cells in the substantia nigra. A related question concerns therelevance of α-synuclein dysfunction to the neurodegenerative process in all cases of Lewy bodydiseases and MSA.  Over the past few years, α-synuclein has become one of only a handful ofproteins that are fundamental to the aetiology and pathogenesis of some of the most commonneurodegenerative diseases. In particular, the detailed mechanisms by which dysfunction of α-synuclein leads to the degeneration of nerve cells remain to be identified. A crucial question iswhether conformationally altered, non-filamentous α-synuclein directly damages nerve cells.Another important question concerns the mechanisms that underlie the assembly of α-synucleininto filaments in idiopathic Lewy body diseases and in MSA. A corollary of this question is how the
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presence of α-synuclein filaments in cell bodies and their processes affects the normal function ofthese cells. Improved experimental animal models will probably be instrumental in providinganswers to these questions. This is especially true of transgenic mouse lines that still fall short ofreplicating many of the most important features of Lewy body diseases.Native synucleins are unfolded proteins with little ordered secondary structure [Weinreb etal., 1996]. However, on binding to lipid membranes or detergent micelles, α-synuclein undergoes astructural transition to α-helical conformation [Davidson et al., 1998; Jo et al., 2000; Perrin et al.,2000; Eliezer et al., 2001]. Both full-length and carboxy-terminal truncated α-synuclein assembleinto filaments that share many of the morphological and ultrastructural characteristics of filamentspresent in humans [Serpell et al., 2000; Conway et al., 1998; El-Agnaf et al., 1998; Giasson et al.,1999; Narhi et al., 1999; Wood et al., 1999; Conway et al., 2000; Giasson et al., 2001]. Assembly is anucleation-dependent process and occurs through the repeats in the amino-terminal half. Thecarboxy-terminal region, in contrast, inhibits assembly. The A53T mutation in α-synucleinincreases the rate of filament assembly, indicating that this might be its primary effect. The effect ofthe A30P mutation on the assembly of α-synuclein is less clear. One study reported an increase infilament assembly, another study found no change, and a third found an inhibitory effect onassembly [Serpell et al., 2000; Narhi et al., 1999; Conway et al., 2000]. The third study showed thatthe A30P monomer was consumed at a similar rate to wild-type α-synuclein, leading to thesuggestion that oligomeric, non-fibrillar α-synuclein species might be detrimental to nerve cells[Conway et al., 2000]. The A30P mutation has also been shown to produce reduced binding of α-synuclein to rat brain vesicles in vitro, indicating that this might lead to its accumulation over time,resulting in filament assembly.The assembly of α-synuclein is accompanied by the transition from random-coilconformation to a β-pleated sheet [Serpell et al., 2000; Conway et al., 2000]. By electron diffraction,
α-synuclein filaments have been found to show a conformation characteristic of amyloid fibres[Serpell et al., 2000]. Under the conditions of these experiments, β- and γ-synuclein failed toassemble into filaments, and remained in a randomcoil conformation [Serpell et al., 2000; Giassonet al 2001]. This behaviour is consistent with their absence from the filamentous lesions of the α-synuclein diseases. It provides further evidence in favour of the hypothesis that α-synucleinaggregation is central to the neurodegeneration observed in Lewy body diseases and MSA.
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Figure 1.10: Model of disease pathway in Parkinson’s disease. Genetic factors (mutations in the α-
synuclein gene and mutations at the PARK3 and PARK4 loci) or environmental factors (oxidative damage, as
exemplified by the experimental effects of rotenone) lead to a dysfunction of α-synuclein, which results in its
ordered assembly into the filaments that characterize Lewy bodies and neurites. It is probable that the space-
occupying Lewy body pathology contributes directly to nerve cell death. In addition, it is possible that
conformationally altered, non-filamentous α-synuclein is toxic to nerve cells. [Reproduced from Goedert et al.,
2001]
[1.3.5.1] α-Synuclein and parkinson’s diseasePD is one of the most frequent neurodegenerative disorders followed by AD, with prevalence closeto 2% after age 65. It is characterized by resting tremor, rigidity, and bradykinesia, which respondwell to levodopa treatment. The pathological hallmarks are the presence of Lewy bodies (LBs) andmassive loss of dopaminergic neurons in the pars compacta of the SN. The cause of this selectiveneurodegeneration is still unknown. Genetic factors, although initially underestimated, havebecome an important issue in PD research. The involvement of susceptibility genes is supported byepidemiological studies that showed a higher frequency of PD in relatives of PD patients than inthose of controls and by elevated concordance in monozygotic twins. In addition, the observationthat the disease is transmitted in some families as an autosomal dominant or an autosomalrecessive trait suggests that mutations in single genes can cause some forms of PD in a monogenicmanner [Goedert et al., 2001].
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Figure 1.11: The α-synuclein pathology of parkinson’s disease. Lewy bodies and Lewy neurites in the
substantia nigra and several other brain regions define Parkinson’s disease at a neuropathological level. Here,
these entities are shown at the light (a–c) and electron microscopic (d–g) levels, labelled by α-synuclein
antibodies. (a) Two pigmented nerve cells, each containing α-synuclein-positive Lewy body (red arrows). Lewy
neurites (black arrows) are also immunopositive. Scale bar, 20 μm. (b) Pigmented nerve cell with two α-
synuclein-positive Lewy bodies. Scale bar, 8 μm. (c) α-Synuclein-positive extracellular Lewy body. Scale bar, 4
μm. (d–g) Isolated filaments from the substantia nigra of patients with Parkinson’s disease are decorated with
an antibody directed against the carboxy-terminal (d and e) or the amino-terminal (f and g) region of α-
synuclein. The gold particles conjugated to the second antibody appear as black dots. Note the uniform
decoration in d and e, and the labelling of only one filament end in f and g. Scale bar, 100 nm. [Reproduced from
Spillantini et al., 1997 and Crowther et al., 2000]
α-Synuclein was the first ‘PD gene’ to be discovered. It is also involved in the pathogenesisof Alzheimer’s disease (AD) and multiple system atrophy (MSA). Although a coherent view of itsrole in normal cell function and in neurodegeneration has not yet emerged, important progress hasbeen made, especially through the identification of a number of partners that interact with α-synuclein. In addition, we are beginning to understand how disruption of normal function and/orprotein aggregation may result in neuronal cell death.
[1.3.5.2] α-Synuclein toxicityThough α-synuclein is the major component of the Lewy bodies, but the main cause of cell death isstill unclear. It has been found that the aggregate of α-synuclein gets deposited into the nerveterminal, and the secretion of dopamine gets decreased from the deposited cells.  While the NACreason is known to be present in an extracellular location, namely, the plaques of Alzheimer’sdisease brains [Ueda et al., 1993], there is as yet no evidence to support the presence of α-synuclein
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in extracellular form. However, if α-synuclein accumulates in neurons (see Figure 1.12), whicheventually die, aggregates could leak out of the dead neuron and spread the disease to neighbouringcells [Mezey et al., 1998]. The toxicity of α-synuclein and NAC is sequence specific and increased byageing in solution, meaning that it is dependent on aggregation and the formation of fibrils similarto the toxicity of other amyloid peptides [reviewed in Lansbury, 1999]. It is also apparent that theamyloidogenic portion of α-synuclein fragment NAC (1–18) mediated the toxic effect of α-synucleinand NAC.
Figure 1.12: Summary schematic of α-synuclein toxicity in a dopaminergic neuron. Lewy bodies, Lewy
neuritis, reactive oxygen species.  [Reproduced from Auluck et al., 2010]Recently [Ostrerova et al., 1999] have studied the effects of overexpressing wild-type ormutant α-synucleins in cells. Their interest in α-synuclein arose from its homology to 14-3-3proteins, a family of protein chaperones expressed in brain. Like 14-3-3, α-synuclein bound to andinhibited protein kinase C and also bound BAD, a protein that regulates cell death. α-Synucleinlevels increased during conditions promoting cell stress, while overexpression of α-synucleinsinduced a dose-dependent increase in toxicity, as measured by trypan blue staining. On the otherhand, reduced expression of α-synuclein by transfection with antisense α-synuclein wascytoprotective.Mutant α-synucleins were more toxic than wild-type α-synuclein, potentiating necrosis. Thetoxicity associated with overexpression of both mutant α-synucleins was probably due to amechanism involving BAD. The ability of α-synuclein and related fragments to cause cell death
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suggests that intracellular accumulation of α-synuclein in neurons and extracellular accumulationof NAC-containing amyloid might contribute to the synaptic loss and cell death that underlies anumber of important neurodegenerative diseases (see Figure 1.12).In general, the toxicity of amyloid proteins is closely associated to the processes ofaggregation and fibril formation. It has been shown that different amyloid proteins share the samemechanism of toxicity to cells in vitro. This mechanism may involve reactive oxygen species and theelevation of intracellular calcium ion levels [Mattson and Goodman, 1995; Schubert et al., 1995].Thus it has been proposed that the ability of amyloid proteins to undergo a transition to β-sheetstructure is a prerequisite to filament formation and subsequent pathological consequences[reviewed in Lansbury, 1999]. It is not clear whether amyloid fibrils are directly toxic or producedamage by the mechanical disruption of tissue. Alternatively, the toxic state may consist of a solubleconformationally altered fibril precursor, or protofibril (see Figure 1.12), that induces cell deathdirectly or indirectly. Accordingly, efforts to elucidate the pathological roles of α-synuclein maylead to improved strategies for the development of novel therapeutic agents for the treatment ofthese important neurodegenerative disorders.
[1.3.6] α-Synuclein interacting moleculesOne of the most fascinating properties of α-synuclein is its ability to react with many other proteins,lipids, drugs and metal ions. α-Synuclein comprises 140 amino acids in two domains, linked via theNAC sequence. The C-terminal domain is rather acidic. The N-terminal domain, which is highlyconserved between species, comprises seven repeats of a degenerate 11-amino-acid motif (residues9–89). This feature is reminiscent of many apolipoproteins that form amphipathic α-helices [Georgeet al., 1995]. α-Synuclein in its native state is unfolded, perhaps explaining its ability to interactwith many other proteins [Weinreb et al., 1996]. However, α-synuclein can bind to small acidicphospholipid vesicles, resulting in a marked increase in α-helicity [Davidson et al., 1998]. Fastaxonal transport of vesicle-bound α-synuclein is dependent on the integrity of the first N-terminalfour of the 11-amino-acid repeats [Jensen et al., 1998]. α-Synuclein (A53T), but not (A30P), wasable to bind these vesicles, perhaps because proline residues disrupt α-helical structure andinterfere with the conformation required for lipid binding. One of the few definite biologicalactivities ascribed to α-synuclein is its inhibition of phospholipase D2, an effect that was dependenton lipid concentration, suggesting that interaction might occur on membrane surfaces [Jenco et al.,1998]. Synphilin-1 has recently been identified, using a yeast two-hybrid system, as a novel proteinthat interacts with α-synuclein in vitro and in vivo. In the brain, synphilin-1 is expressed in many
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areas, including the substantia nigra. In cells cotransfected with synphilin-1 and NAC the formationof cytoplasmic inclusions was observed. Cotransfection with full-length α-synuclein wild-type orA53T mutant did not lead to the formation of inclusions [Engelender et al., 1999]. This may bebecause NAC aggregates faster than full-length α-synuclein [El-Agnaf et al., 1998]. It will beinteresting to discover whether synphilin-1 is a component of Lewy bodies and Lewy neurites.Since NAC was discovered as a component of senile plaque amyloid in AD brains, and the similarityin sequence between NAC and Aβ was noted (see Figure 1.9), it was of considerable relevance toinvestigate its interaction with Aβ. Preformed NAC fibrils were found to seed the aggregation of Aβ(1–40) and, vice versa, Aβ fibrils could seed NAC aggregation [Han et al., 1995]. It has also beenreported that α-synuclein can bind Aβ (25–35) and that the NAC region is crucial to this interaction[Yoshimoto et al., 1995]. Binding of α-synuclein to Aβ is dependent on two domains in the formerprotein encompassing residues 1–56 and 57–97, respectively [Jensen et al., 1997].
[1.3.6.1] α-Synuclein shares physical and functional homology with 14-3-3 proteinsα-, β- and γ-synucleins show homology to a region of the 14-3-3 proteins and may be members ofthis superfamily [Ostrerova et al., 1999]. Like these proteins, α-synuclein binds to extracellularregulated kinase (ERK), dephospho-BAD (a Bcl-2 homolog) and protein kinase C (PKC) indecreasing order of affinity, but also to the 14-3-3 proteins themselves.
Figure 1.13: Alignment of α-synuclein and the 14-3-3 family of proteins. The alignment was performed
using the Multalin program (http://www.toulouse.inra.fr/multalin.html). To observe homology, the first 30
amino acids of 14-3-3 proteins were excluded while performing the alignment algorithm. Exact matches are
shown as white letters on a black background, and matches of proteins with similar properties are shown as
black letters on a gray background. [Reproduced from Ostrerova et al., 1999]
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The affinity of membrane-bound α-synuclein for different PKC isoforms also differs (α = γ >ε > β = δ). Forced expression of wild-type or A53T α-synuclein in human embryonic kidney (HEK)cells inhibited PKC activity. Although α-synuclein and 14-3-3 both bind to BAD, the interactions areindependent, the former binding dephospho-BAD, the latter, phospho-BAD [Ostrerova et al., 1999].Since ERK, BAD, and PKC are involved in the regulation of cell viability, α-synuclein may play a rolein the same signaling pathways.
[1.4] Amyloid-beta (Aβ)Amyloid-beta (Aβ) is a 36-43 amino acid long peptide that is derived from the Amyloid precursorprotein and the aggregation and fibril formation of amyloid-beta peptide are the main cause ofpathogenesis and development of AD [Naslund et al., 2000; Selkoe et al., 2001].  There are differentisoforms of Aβ have been reported that differ by the number of amino acids at the C terminus[Selkoe et al., 1999]. Specifically, the 40-residue (Aβ40) and 42-residue (Aβ42) isoforms both havebeen associated with AD. In particular, Aβ42 shows a high propensity to self-assemble and depositin senile plaques and is highly toxic for neurons [Findeis et al., 2007], and its overproduction hasbeen related to familiar forms of AD [Scheuner et al., 1996].Aggregation of Aβ42 is a complex process that involve in the formation of several solubleintermediate species, including oligomeric and protofibrillar forms, and ends with the deposition ofordered fibrillar architectures whose three-dimensional structure has been recently published[Luhrs et al., 2005]. The process of in vivo polymerization is poorly understood, and thepathological role of different soluble species is still controversial. For instance, although theamyloid plaques are a major hallmark of AD, they are only part of an array of Aβ aggregatemorphologies observed in vivo [Walsh et al 2004]. Interestingly, not all of these Aβ assembliesprovoke an inflammatory response and are toxic. The detailed pathological mechanism still remainsunclear. Considerable evidence suggests that soluble ordered oligomeric intermediates (e.g., solubleoligomers [56 kDa] and protofibrils), rather than insoluble peptide deposits, exert cytotoxic effectsand play a crucial role in AD onset and progression [Glabe et al., 2006; Lambert et al., 1998; Walshet al., 2002]. Aβ deposits may enhance oxidative stress and inflammation, leading to cell injury[Varadarajan et al., 2000].Despite this acute importance and interest, there are several aspects of amyloid aggregationthat conspire against reliable experimental studies and direct comparison of the results. First, thekinetics of Aβ42 aggregation is very sensitive to inputs, such as the conformational status ofstarting material [Sandal et al., 2008] and physicochemical characteristics of the solution
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[Hortschansky et al., 2005], and studies are limited by the poor water solubility of Aβ42. Indeed,depending on experimental conditions and the detection system, different on- and off-pathwayintermediates have been reported, resulting in divergent kinetics and aggregation models[Hortschansky et al., 2005; Necula et al., 2007; Zhu et al., 2004]. Second, the structuralpolymorphism (i.e., the tendency to aggregate into multiple morphologies, which is a prominentfeature of Aβ aggregation) makes the reliable in vitro reproduction of neurotoxicity relatedassembly difficult, thereby leading to contradictory study outcomes.
[1.4.1] Amyloid-beta in neurodegenerative diseaseAmyloid plaques are not only a histopathological hallmark of AD, but the aggregated Aβ of whichthey are composed likely play a key role in the pathogenesis of AD [Hardy et al., 2001]. The mostdirect evidence supporting this hypothesis stems from studies of gene mutations that causeautosomal-dominant inherited forms of AD. As illustrated in Figure 1.14, most but not all of thesemutations lead to increased production and accumulation of specific Aβ species (Aβ42), eitherthrough effects on the amyloid precursor protein (APP) itself [Goate et al., 1991] or through effectson presenilin 1 or 2 [Scheuner et al., 1996], which form part of γ-secretase, one of the proteolyticcomplexes that cleaves APP to generate Aβ [Wolfe et al., 1999]. Aggregated amyloid (in the form ofoligomers, protofibrils, or fibrils) is toxic to neurons in most but not all culture conditions [Yankneret al., 1996 and Kayed et al., 2003], and in primary neuronal culture and mouse models, Aβ may actsynergistically with neurofibrillary tangle pathology [Rapoport et al., 2002 and Lewis et al., 2001].These observations have led to the hypothesis that increased production, aggregation, andaccumulation of Aβ initiates a cascade of events leading to neurotoxicity and eventually to clinicalsymptoms of AD [Hardy et al., 2001], as summarized in Figure 1.14. Autopsy studies of patientswith genetic forms of AD, Down’s syndrome, or mild cognitive impairment (which appears to be aprodromal phase of AD) have shown that accumulation of Aβ may precede clinical development ofAD by as many as 10 years [Mann et al., 1989; Lemere et al., 1996; Smith et al., 2001; Morris et al.,1996]; importantly, the increased presence of Aβ correlates well with cognitive decline early in thecourse of the disease [Naslund et al., 2000].  Thus, Aβ pathology (a) is required for the diagnosis ofAD, (b) plays a key role in the pathogenesis of AD, and (c) develops prior to symptomaticmanifestations of AD. For these reasons, there has been great interest in developing therapies anddiagnostic tools aimed at Aβ.
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Figure 1.14: Aβ production. The integral membrane protein amyloid precursor protein (APP) is cleaved by the
beta-site APP-cleaving enzyme (BACE, or β-secretase) to yield a secreted fragment of APP (sAPPβ) and a C-
terminal fragment of APP (CTFβ). CTFβ is then cleaved by γ-secretase within the membrane to yield a smaller C-
terminal fragment (CTFγ) and Aβ fragments of various lengths (shown in red). An alternate cleavage by α-
secretase (not shown) cuts within the Aβ domain and thus precludes Aβ production. Potential opportunities for
therapeutic intervention are shown in the blue boxes. [Skovronsky et al., 2006]
[1.5] 14-3-3 ProteinsThe 14-3-3 proteins were initially described as an acidic, abundant brain protein by Moore & Perezin 1967 [Moore et al., 1967]. The name is derived from the combination of its fraction number onDEAE-cellulose chromatography and its migration position in the subsequent starch–gelelectrophoresis. The unique terminology remains while the concept of 14-3-3 has evolved from abrain-specific protein to a family of ubiquitously expressed regulatory molecules of eukaryoticorganisms. 14-3-3 has emerged as a group of multifunctional proteins that bind to and modulatethe function of a wide array of cellular proteins. More than 50 signaling proteins have beenreported as 14-3-3 ligands. This broad range of partners suggests for 14-3-3 a role as a generalbiochemical regulator, reminiscent of the well-defined regulatory protein calmodulin. Throughinteraction with its effector proteins, 14-3-3 participates in the regulation of diverse biologicalprocesses, including neuronal development, cell growth control, and viral and bacterialpathogenesis. This chapter focuses on recent developments in the understanding of the structuralbasis of 14-3-3 and α-synuclein interactions and on roles for 14-3-3 on α-synuclein aggregation.The functions of 14-3-3 in neuronal development, signal transduction [Aitken et al., 1996; Morrisonet al., 1994; Pawson et al., 1997], and plant biology [Ferl et al., 1996 and Finnie et al., 1999] haverecently been reviewed elsewhere.
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[1.5.1] General properties14-3-3 is a family of highly homologous proteins encoded by separate genes. There are sevenknown mammalian 14-3-3 isoforms, named with Greek letters (β, ε, γ, η, σ, τ, ζ) after their elutionprofile on reversed phase high-performance liquid chromatography [Ichimura et al., 1988 andMartin et al., 1993]. The species initially designated α and δ are actually the phosphorylated formsof β and ζ [Aitken et al., 1995]. The 14-3-3 proteins exist mainly as dimers with a monomericmolecular mass of approximately 30,000 Da and an acidic isoelectric point [Morrison et al., 1994;Pawson et al., 1997].14-3-3 proteins exhibit a remarkable degree of sequence conservation between species[Wang et al., 1996]. For example, the Saccharomyces cerevisiae BMH1 and human ε isoforms areapproximately 70% similar at the amino acid level. 14-3-3 proteins also share some basicbiochemical properties, such as activation of the ExoS ADP-ribosyltransferase [Fu et al., 1993;Zhang et al., 1999] and of tryptophan hydroxylase [Isobe et al., 1991]. These similarities arguestrongly for a high degree of functional conservation.14-3-3 is abundant in the brain, comprising approximately 1% of its total soluble protein[Boston et al., 1982]. It is now clear that 14-3-3 is also present in almost all tissues, including testes,liver, brain and heart [Celis et al., 1990]. Within a eukaryotic cell, 14-3-3 is largely found in thecytoplasmic compartment. However, 14-3-3 proteins can also be detected at the plasma membraneand in intracellular organelles such as the nucleus and the Golgi apparatus [Celis et al., 1990; Freedet al., 1994; Fanger et al., 1998; Leffers et al., 1993; Tang et al., 1998]. Like their high degree ofconservation, the ubiquitous nature of 14-3-3 proteins may reflect their fundamental importance ineukaryotic biology. Indeed, recent research on 14-3-3 supports this view.The frequent isolation of 14-3-3 from many biochemical and genetic screens for differenttargets must reflect the physiological importance of 14-3-3 in diverse cellular pathways. Dependingon its interaction with specific effectors, 14-3-3 participates in many vital regulatory processes,such as cell cycle control, survival signaling, cell adhesion, and neuronal plasticity. The trend ofrediscovery of 14-3-3 proteins shows no sign of diminishing and in fact will likely become morecommon because of an increased understanding of the regulation of 14-3-3–ligand interactions.
[1.5.2] Structural basis
[1.5.2.1] 14-3-3 monomer contains a conserved amphipathic grooveThe drive to understand the molecular mechanisms by which 14-3-3 interacts with its ligands led tothe solution of the crystal structures of 14-3-3ζ [Liu et al., 1995] and 14-3-3τ [Xiao et al., 1995],
- 44 -
revealing strikingly similar dimeric structures. Each monomer consists of a bundle of nine α-helicesorganized in an antiparallel fashion [Fu et al., 2000]. The molecule has a cup-like shape with ahighly conserved, inner, concave surface and a variable outer surface (see Figure 1.15). A strikingfeature of the concave surface is an amphipathic groove in each monomer [Fu et al., 2000]. Asrevealed from the ζ structure [Liu et al., 1995], on one side of the groove, helices 3 and 5 present acluster of charged and polar residues. On the other side of the groove, helices 7 and 9 present apatch of hydrophobic residues. It is interesting to note that these residues lining the concavesurface of the groove are mostly conserved among different isoforms of the 14-3-3 family [Yaffe etal., 1997; Liu et al., 1995; Xiao et al., 1995; Petosa et al., 1998]. Because many 14-3-3 ligands bindwell to all isoforms, it was thought that this conserved amphipathic groove could mediate thebinding of 14-3-3 to its target proteins [Liu et al., 1995]. It was further postulated that a basiccluster in the groove, consisting of K49, R56, and R127, may mediate the interaction of 14-3-3 withthe phosphoamino acid in its ligands. This model has been unequivocally confirmed by bothmutational analysis [Zhang et al., 1997; Wang et al., 1998; Thorson et al., 1998] and co-crystallization studies [Yaffe et al., 1997; Rittinger et al., 1999; Petosa et al., 1998]. 14-3-3ζ has beenco-crystallized in complex with several peptide ligands, providing critical insights into thestructural details of 14-3-3–ligand interactions [Yaffe et al., 1997; Rittinger et al., 1999; Petosa et al.,1998].
In the complexes, both phosphorylated and unphosphorylated 14-3-3 binding peptides liein the conserved amphipathic groove [Fu et al., 2000]. Instead of the α-helical structure originallyproposed, 14-3-3 binding peptides adopt an extended conformation. These extended structuresmay have fewer steric constraints and greater conformational flexibility to sample differentresidues in the groove for optimal association. This gives 14-3-3 great versatility in the recognition
Figure 1.15: Crystal structure of 14-3-3 η
dimer.
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of a diverse range of ligand sequences. The high-resolution model of 14-3-3ζ in complex with amode 1 phosphoserine peptide derived from MT (MARSHpSYPAKK) provides a structuralexplanation for the 14-3-3–phosphoserine motif interaction [Yaffe et al., 1997; Rittinger et al.,1999]. The phosphoserine contacts 14-3-3 by salt bridges to the side chains of K49, R56, and R127in the basic cluster and a hydrogen bond to the hydroxyl group of Y128 [Fu et al., 2000]. In supportof this interpretation, charge-reversal mutations K49E, R56E, and R127E drastically disrupt theinteraction of 14-3-3ζ with Raf-1 and Bcr. K120 in the charged face of the groove, together withN173 and N224, stabilize an extended ligand conformation by contacting backbone groups of the +1and –1 residues, which may be important for positioning the phosphoserine to interact with thebasic cluster of 14-3-3. All of these interactions were similar for a synthetic peptide based on themode 2 binding motif [Rittinger et al., 1999], which suggests that diverse ligands use the basiccluster and its accessory residues to bind to 14-3-3. Outside of this cluster, there is considerablevariability in 14-3-3–ligand connections, as assessed by comparison of the MT co-crystal structurewith that of the mode 2 peptides. For example, E180 forms a hydrogen bond with the –2 Ser in theMT peptide but bonds with the –4 Arg in the mode 2 peptides [Rittinger et al., 1999]. Similarly,several hydrophobic residues, including L172, L216, I217, and L220, are consistently involved inbinding, but they interact with different parts of the two ligands. This type of flexible interactionmay explain the diversity among 14-3-3 binding sequences from various ligands. The conservedligand binding groove is also involved in binding unphosphorylated ligands, such as R18 [Fu et al.,2000]. R18 is a peptide selected from a phage display library for its high affinity for 14-3-3 proteins[Wang et al., 1999]. In the 14-3-3ζ–R18 complex, R18 assumes an extended conformation in theamphipathic groove, similar to phosphorylated peptides [Petosa et al., 1998]. Its core WLDLEsequence is located in the phosphoserine binding site with its two acidic residues, Asp and Glu, nextto the basic cluster of 14-3-3. Two Leu of R18 interact with amino acids on the hydrophobic side ofthe 14-3-3 groove, including L172 and L220. Thus, R18 assumes a true amphipathic structure.It has been reported that C-terminal fragments of 14-3-3 are capable of ligand binding [Luoet al., 1995; Ichimura et al., 1995; Gu et al., 1998]. For example, the ‘‘box-1’’ region, which spansresidues 171–213 of 14-3-3η, efficiently binds tryptophan hydroxylase, Raf-1, and Bcr [Ichimura etal., 1995; Ichimura et al., 1997]. Although several hydrophobic and polar residues that contribute tothe ligand binding groove of 14-3-3 are located in these regions, the exact nature of the stableinteraction of these regions with different proteins remains to be clarified.
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[1.5.2.2] 14-3-3 dimer can simultaneously bind two ligandsAs seen in the various crystal structures, the N-terminal portion of 14-3-3 is involved in dimerformation [Fu et al., 2000; Liu et al., 1995; Xiao et al., 1995]. The dimer interface is formed by thepacking of helix α1 from one monomer against α3 and α4 from the other, leaving a 6- to 8-Å hole inthe center. Several hydrophobic and polar residues are buried in the dimer interface, including L12,A16, V62, I65, and Y82. These residues are largely conserved among mammalian 14-3-3 isoforms,which raises the possibility that 14-3-3 proteins can form heterodimers between different isoforms[Jones et al., 1995]. The dimeric structure of the 14-3-3 protein allows it to bind two ligandssimultaneously (Figure 1.16 a, b). In the co-crystal structures of 14-3-3 with peptides, the ligandbinding sites are located within the same concave surface, and each site is occupied [Yaffe et al.,1995; Petosa et al., 1998]. The dimer is arranged such that the ligand binding groove runs inopposite directions in each monomer of the molecule (Figure 1.16b). Simultaneous binding of a14-3-3 dimer to two protein ligands would have significant implications.
Figure 1.16: Crystal structural model of 14-3-3ζ. (a) 14-3-3ζ crystallized with R18 (PDB ID 1A38), rotated
90° relative to (b) Solvent accessible surface of 14-3-3ζ with bound peptides (represented by arrows).
Dimerization forces bound ligands to adopt opposite orientations. [Reproduced from Fu et al., 2000]In this regard, it is interesting to note that many 14-3-3 ligands, such as Raf-1 and Cbl, havemultiple recognition motifs. Dual recognition by 14-3-3 of two weakly interacting motifs, such asthose found in Cbl, may promote a more stable interaction. In contrast, 14-3-3 may bind to twohigh-affinity sites, such as those found in Raf-1, perhaps to promote a regulatory conformationalchange in Raf-1. Alternatively, 14-3-3 may bring together two different signaling molecules tomodulate each other’s activity. Some evidence has been provided that 14-3-3 can mediate theassociation of Raf-1 with Bcr [Braselmann et al., 1995] or A20 [Vincenz et al., 1996], but thephysiological significance of these complexes is unclear. It is plausible that this adaptor function of
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14-3-3 exists only for specific ligand pairs. Yet another possible role for dimerization of 14-3-3 is insubcellular localization. For example, one monomer could function as a targeting unit by binding ananchored ligand while the other binds a cargo protein. Depending on the site of the anchoredligand, 14-3-3 may localize the cargo protein to distinct intracelluar compartments. The recentlyreported binding of 14-3-3 to CRM1 may serve such a purpose [Rittinger et al., 1999].Although the exact function of 14-3-3 dimerization is not clear, the importance of thisphenomenon is supported by data showing that several ligand binding–defective mutants of 14-3-3act as dominant negative inhibitors in vivo [Thorson et al., 1998; Chang et al., 1997; Zhang et al.,1999a; Zhang et al., 1999b]. The dimeric nature of 14-3-3 may hold the key for many critical roles of14-3-3 in cells.
[1.5.3] Disease associated with 14-3-3 proteinsAlthough 14-3-3 has not been directly linked to a specific disease, it has been implicated in a varietyof pathological processes. A large number of 14-3-3 ligands are proto-oncogene or oncogeneproducts, which suggests the participation of 14-3-3 in mitogenic signal transduction as well asneoplastic transformation. Indeed, the tumor profile of mice infected with polyomavirus expressinga 14-3-3 binding–defective mutant MT showed a striking deficiency in the induction of salivarygland tumors [Cullere et al., 1998]. Another possible connection of 14-3-3 to tumorigenesis is itsinvolvement in regulating cell survival, for example through its interaction with IGFIR. The IGFIRplays an important role in controlling normal cell survival as well as in tumorigenesis [Baserga etal., 1997]. The major site for 14-3-3 interaction is located within a Ser quartet critical for IGFIR-mediated cell transformation [Craparo et al., 1997; Furlanetto et al., 1997;  Li et al., 1996], implyingthat 14-3-3 participates in this process. Significantly elevated levels of both the IGFIR [Kaiser et al.,1993] and 14-3-3 proteins [Nakanishi et al., 1997] have been detected in all major types of lungcancer. On the other hand, the 14-3-3ε gene is found in a region with frequent loss of heterozygosityin several cancers, which suggests that some 14-3-3 isoforms may be important for suppression oftumorigenesis [McDonald, 1994]. Taken together, these data argue that 14-3-3 may be involved inthe development of human cancer.The abundance of 14-3-3 proteins in brain tissues points to a critical role of 14-3-3 inneuronal function. There are some indications that 14-3-3 is involved in several neurologicaldisorders. 14-3-3ε is located in a chromosomal region, 17p13.3 that contains genes implicated inisolated lissencephaly sequence (ILS) and Miller-Dieker syndrome (MDS) [Chong et al., 1997;Hirotsune et al., 1997]. ILS is a brain malformation malady marked by disorganization of the
- 48 -
cortical layers. MDS causes malformations similar to those of ILS, as well as additionalabnormalities, and is associated with larger deletions of 17p13.3. The 14-3-3ε sequence is deletedin some MDS patients, and this loss may contribute to the development of MDS phenotypes [Chonget al., 1997]. 14-3-3 proteins are also found in the neurofibrillary tangles seen in patients withAlzheimer’s disease [Layfield et al., 1996]. A possible genetic association of a 14-3-3ηpolymorphism with early onset schizophrenia has been reported [Toyooka et al., 1999]. Hsich et al.,[1996] noted that 14-3-3 proteins are specifically detected in cerebrospinal fluid from patients withCreutzfeldt-Jakob disease (CJD) and related transmissible spongiform encephalopathies. Thisobservation has allowed the use of 14-3-3 as a biochemical marker for a premortem diagnostic testfor CJD and related diseases [Hsich et al., 1996; Moussavian et al., 1997]. It is not known whether14-3-3 is involved in the pathogenesis of CJD, or whether the presence of 14-3-3 in cerebrospinalfluid is simply the consequence of neuronal cell death in CJD brains.
Table 1.3:Milestones in 14-3-3 research
Year Function , System, Specific finding References1968 Naming; identification as abundant brain proteins Moore et al., 19671980 Purification and axonal transport Erickson et al., 19801982 14-3-3 in cerebro spinal fluid Boston et al., 19821987 Enzyme regulation; activation of tryptophan and tyrosine monooxygenase Ichimura et al., 19871988 Separation by HLPC and naming of brain forms by greek letters; cloning of 14-3-3 Ichimura et al., 19881990 Interaction with a kinase (inhibition of PKC) Aitken et al., 19901992 Exocytosis (Exo1) Morgan et al., 199214-3-3 in other eukaryotes: yeast, plant and Xenopus 14-3-3 Van-Heusden et al., 1992G-box binding factor, GF14 Lu et al., 1992Phosphorylated forms of 14-3-3 Toker et al., 19921993 Exoenzyme S Fu et al., 19931994 AANAT and 14-3-3 Roseboom et al., 199414-3-3 association with Raf kinase Fantl et al., 1994Receptors: fusicoccin receptor/binding protein Marra et al., 1994Association with c-Bcr and Bcr-Abl Reuther et al., 1994Association of polyomavirus middle tumour antigen with 14-3-3 Pallas et al., 199414-3-3 fission yeast homologues and DNA damage checkpoint Ford et al., 1994EF-hand calcium binding motif in sub-class of plant 14-3-3s Lu et al., 19941995 14-3-3α and δ are the brain phosphorylated 14-3-3β and ζ Aitken et al., 1995Crystal structures of 14-3-3 Xiao et al., 1995Heterodimers Jones et al., 1995Stage-specific expression of 14-3-3 during life cycle of Schistosoma mansoni Schechtman et al., 1995Phosphatidylinositol 3-kinase association Schechtman et al., 1995b14-3-3 association with phosphatase (Cdc25) Conklin et al., 1995
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[1.5.4] Co-localization of 14-3-3 protein in Lewy- bodiesParkinson’s disease (PD), one of the most common neurodegenerative diseases, is characterizedneuropathologically by the presence of intracytoplasmic inclusions called Lewy bodies (LBs), whichmainly contain aggregated α-synuclein [Spillantini et al., 1997]. Point mutations in the α-synucleingenes have been discovered in families afflicted with autosomal dominant inherited PD [Kruger etal., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004]. α-Synuclein is expressedpredominantly in the presynaptic nerve terminals [George et al., 1995]. Under normal conditions, itis thought to have a role in the modulation of synaptic vesicle turnover and synaptic plasticity[Chandra et al., 2005; Clayton et al., 1999]. However, this physiological role of α-synuclein is notessential for nerve terminal function, because α-synuclein knockout mice display only a mildphenotype. Nevertheless, α-synuclein is likely to protect nerve terminals under unusual conditionssuch as neuronal stress or injuries, since the transgenic expression of α-synuclein has been shownto abolish the lethality and neurodegeneration caused by the deletion of cysteine-string protein-(CSP), a co-chaperone protein localized in the synaptic vesicles [Chandra et al., 2005]. Therefore,the loss of functional α-synuclein may predispose dopaminergic neurons to oxidative injury ormitochondrial dysfunction.Lewy bodies also contain other proteins including ubiquitin [Lowe et al., 1988], parkin[Shimura et al., 2001], cytoskeletal proteins like neuroinflaments [Schmidt et al., 1991], and septins[Ihara et al., 2003], 14-3-3 proteins [Kawamoto et al., 2002a], and synphilin-1 [Wakabayashi et al.,2001]. The 14-3-3 proteins, a family of protein chaperones, are abundant in the brain, comprisingapproximately 1% of the total brain proteins [Boston et al., 1982]. 14-3-3 proteins consist of sevendifferent isoforms [Fu et al., 2000]. 14-3-3 proteins exist mainly as homo- or hetero-dimersconsisting of ε and ζ, or τ and ζ subunits, and participate in intracellular signal transductionpathways [Aitken et al., 1996]. 14-3-3 Proteins are increased in the cerebrospinal fluid frompatients with Creutzfeldt-Jakob disease (CJD), and the detection of 14-3-3 proteins is a marker inthe pre-mortem diagnosis of CJD [Hsich et al., 1996]. In recent studies, 14-3-3 proteins were foundin abnormal pathological structures, including the neurofibrillary tangles in AD [Layfield et al.,1996], the Pick bodies in Pick’s disease [Umahara et al., 2004], the Lewy bodies in PD [Kawamoto etal., 2002b], the Lewy body-like hyaline inclusions in amyotrophic lateral sclerosis [Kawamoto et al.,2004], the glial cytoplasmic inclusions in multiple system atrophy [Kawamoto et al., 2002a], thenuclear inclusions in spinocerebellar ataxia-1 [Chen et al., 2003], the prion plaques in sporadic CJD,and the florid plaques in variant CJD [Richard et al., 2003]. Ostrerova et al. [Ostrerova et al., 1999]showed that regions of α-synuclein and 14-3-3 proteins share over 40% homology, and bind to
- 51 -
each other. These proteins were found to oppositely regulate parkin activity [Sato et al., 2006],suggesting important roles for 14-3-3 and α-synuclein together with parkin in the pathogenesis ofPD. On the other hand, Engelender et al. [Engelender et al., 1999] identified synphilin-1, a novelprotein which also interacts with α-synuclein to form cytoplasmic inclusions in vitro. The C-terminus of synphilin-1 is closely associated with the C-terminus of α-synuclein [Kawamata et al.,2001]. The function of synphilin-1 is not fully understood yet; however, it is enriched in thepresynaptic terminals, possibly mediating the synaptic function attributed to α-synuclein [Ribeiroet al., 2002]. Synphilin-1 is enriched in the central cores of LBs, and is presumed to play a role in LBformation in vivo [Wakabayashi et al., 2000]. Recently, Eyal et al. [Eyal et al., 2006] identifiedsynphilin-1A, an isoform of synphilin-1, which has enhanced aggregatory properties and causesneurotoxicity. Synphilin-1A is also observed in LBs. Synphilin-1 and synphilin-1A differs in theirexon organization, and is translated from different start codons. Therefore, the N-terminus ofsynphilin-1A is different from that of synphilin-1. In addition, a mutation of the synphilin-1 genehas been detected in two German PD patients. Collectively, clarifying the roles of α-synuclein, 14-3-3, and synphilin-1 in the process of LB formation may shed some light on the pathogenesis of PD. Inthis study, we examined A53T-Tg mice, which overexpress mutated human A53T α-synucleinunder the control of a prion promoter, using immunohistochemistry for α-synuclein, the seven 14-3-3 isoforms, and synphilin-1. α-Synuclein has a tendency to selfaggregate and form fibrils in thepresence of the familial PD-linked A53T mutation of α-synuclein [Conway et al., 1998], and theA53T-Tg mice show numerous α-synuclein-based aggregates in the brain [Giasson et al., 2002]. Wedetermined the distribution of the seven 14-3-3 isoforms and synphilin-1 in the aggregates fromthese mice to uncover the roles of 14-3-3 proteins and synphilin-1 in the pathogenesis of PD.
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[1.5.5] Sequence similarity between 14-3-3η and α-synuclein
Figure 1.17:Multiple sequence alignment of α-synuclein and 14-3-3η showing alignment score 47.
Single letter: amino acids, Red: small, hydrophobic, aromatic, Blue: acidic,Magenta: basic, Green: hydroxyl, amine, amide
“*”: Identical
“:”: Conserved substitution (similar color group)
“.”: Semi conserved substitution (similar shapes)
Score: 47
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[1.5.6] Sequence similarity between 14-3-3 η and 14-3-3γ14-3-3 γ belongs to the 14-3-3 family of proteins which mediate signal transduction by binding tophosphoserine-containing proteins. It is induced by growth factors in human vascular smoothmuscle cells, and is also highly expressed in skeletal and heart muscles, suggesting an importantrole for this protein in muscle tissue.
Figure 1.18:Multiple sequence alignment of 14-3-3γ and 14-3-3η.
Single letter: amino acids, Red: small, hydrophobic, aromatic, Blue: acidic,Magenta: basic, Green: hydroxyl, amine, amide
“*”: Identical
“:”: Conserved substitution (similar color group)
“.”: Semi conserved substitution (similar shapes)14-3-3γ and 14-3-3η shows more than 95% sequence similarity. Nevertheless, 14-3-3η does notinteract with α-synuclein.
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Chapter-2
(Results and Discussion)
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Morphological Analysis of Proteins
[2.1] α-Synuclein
[2.1.1] Monomer
α-Synuclein is a 140 aa long polypeptide chain that acquires partially unfolded state when it comesin contact with solution. It is very difficult to see α-synuclein monomer by AFM Probe being theirend radius of curvature of the order of 10 nm.
[2.1.2] Oligomers
α-Synuclein acquires different conformations in solution state which leads to the formation ofdifferent kind of oligomers. These oligomers are considered as a most toxic species in PD. There areseveral factors (e.g. temperature, metal ions, pesticides, herbicides, chaperone protein etc.) thatinfluence the α-synuclein aggregation, and leads to the formation of morphologically distinctoligomers [Uversky et al., 2007].
Figure 2.1: AFM image analysis of early-formed α-synuclein oligomers. (a) Early-formed α-synuclein
oligomers (2μm×2μm), (b) Early-formed α-synuclein oligomers (1μm×1μm), (c) Height profile of early-formed α-
synuclein oligomers (heights were measured between 2.5–5 nm).
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α-Synuclein forms oligomers of height between 2–8 nm [Lowe et al., 2004]. There areseveral other factors that stimulate α-synuclein aggregation and leads to the formation ofmorphologically distinct and bigger oligomers.  In case of adding metal ions (e.g., Co²⁺, Cd²⁺, Ca²⁺ions) in α-synuclein solution, α-synuclein forms oligomers of 30–50 nm in diameter [Lowe et al.,2004]. We observed oligomers which supports the data which has been reported previously.The early formed oligomers were observed by incubating α-synuclein (80 μM) in 200 μl ofPBS buffer (50 mM, pH 7.4) at 37 °C for 2–6 h with continuous shaking at 1000 rpm (see section3.2.1 in detail for protein aggregation). Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis). Theimage analysis was based on the shapes and heights of oligomers. In fact their lateral dimensionobserved by AFM is expected to be much larger than the real one due to the well known tip-broadening effect, contrary to their height that is correctly reproduced in the AFM images, instead.Heights of the oligomers were measured between 2.5–5 nm which is compatible with the expectedheight of early formed oligomers.
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Figure 2.2: AFM image analysis of belatedly-formed α-synuclein oligomers. (a) Belatedly-formed α-
synuclein oligomers (2μm×2μm), (b) B elatedly-formed α-synuclein oligomers (1μm×1μm), (c) Height profile of
belatedly-formed α-synuclein oligomers (heights were measured between 5–8 nm).Also heights between 5–8 nm were measured at 6–12 h. These values are compatible withthe height of belatedly-formed mature oligomers, instead [Conway et al., 2000a].
[2.1.3] Morphologically distinct oligomers
Figure 2.3: AFM image analysis of non-spherical α-synuclein oligomers. (a) α-Synuclein oligomers
(5μm×5μm), (b) α-Synuclein oligomers (2μm×2μm), (c) Height profile of α-synuclein oligomers (heights were
measured between 5–7 nm and diameters were measured between 30–70 nm).Diverse morphological shapes of α-synuclein oligomers were observed. The average height of non-spherical (angular shaped) oligomers were measured was ~5.5 nm and diameters were measuredbetween 30–70 nm. It is expected that the morphological appearance of oligomers depends on the
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conformations of the α-synuclein monomer which participates in protein aggregation [Uversky etal., 2007].
[2.1.4] ProtofilamentsProtofilaments were observed after 12–13 days long incubation of α-synuclein (80 μM) in 200 μl ofPBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (see section 3.2.1 indetail for protein aggregation). Images were taken in tapping mode AFM, and analyzed by Scanningprobe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).
Figure 2.4: AFM image analysis of α-synuclein protofilaments. (a) Bundles of protofilaments, (b) Height
profile of protofilaments (height measured between 2.5–3.5 nm).We observed bundles of α-synuclein mature fibrils only after 5–6 days of incubation at 37°Cwith continuously shaking at 1000 rpm. The observation of α-synuclein protofilaments afterforming α-synuclein mature fibrils show that the formation of protofilaments was initiated bymature fibrils. Heights of the protofilaments were measured between 2.5–4.5 nm. These values arecompatible with the heights of protofilaments reported previously [Conway et al., 2000b; Ding etal., 2002].
[2.1.5] ProtofibrilsProtofibrils were observed after 13–15 days long incubation of α-synuclein (80 μM) in 200 μl ofPBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (see section 3.2.1 indetail for protein aggregation). Images were taken in tapping mode AFM, and analyzed by Scanningprobe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).
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Figure 2.5: AFM image analysis of α-synuclein protofibrils. (a) α-Synuclein protofibrils (1.5μm×1.5μm), (b)
α-Synuclein protofibrils (1μm×1μm), (c) Height profile of α-Synuclein protofibrils (height was measured between
4 nm – 6 nm), (d) Height profile of single α-synuclein protofibril (~4.5 nm).We observed bundles of α-synuclein mature fibrils only after 5–6 days. The observation of
α-synuclein protofibrils after forming α-synuclein mature fibrils shows that the formation ofprotofibrils was initiated by mature fibrils. Heights of the protofibrils were measured between 4–6nm. These values are compatible with the heights of protofibrils reported previously [Conway et al.,2000b; Ding et al., 2002].
[2.1.6] Mature fibrilsApart from studying oligomers, protofilaments and protofibrils we also studied two different kindsof mature fibrils, mature fibrils with twist and mature fibrils without twist. Those fibrils wereobserved after incubating α-synuclein (80 μM) in 200 μl of PBS buffer (50 mM, pH 7.4) at 37 °C for3–6 days with continuous shaking at 1000 rpm (see section 3.2.1 in detail for protein aggregation).
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Images were taken in tapping mode AFM, and analyzed by Scanning probe microscopy software,WSxM 5.0 (see section 3.2.4 in detail for image analysis).
Figure 2.6: AFM image analysis of α-synuclein mature fibrils. (a) α-Synuclein mature fibrils (2μm×2μm),
(b) α-Synuclein mature fibrils (1μm×1μm), (c) Both twisted and untwisted α-synuclein mature fibrils
(1μm×1μm),(d) Height profile of a single left handed twisted α-synuclein mature fibrils (height was measured
between 5–7 nm). The periodical arrangement of twist in the mature fibrils (measured ~2 nm depth and ~100
nm width), (e) Height profile of α-synuclein mature fibrils (measured between 7–9 nm), (f) Height profile of
twisted (~8.5 nm) and untwisted (~5.5 nm) α-synuclein mature fibrils, (g) Kinetics measurement of α-synuclein
mature fibrils. The average height of fully formed mature fibrils was measured around ~9 nm.
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The height of twisted α-synuclein mature fibrils was measured around 8 nm and height ofuntwisted α-synuclein mature fibrils was measured around 6 nm. There are several hypothesishave been proposed about the fibrils assembly, which suggest that the protofibrils are formed bythe combination of 2–3 protofilaments, furthermore diameter of mature fibrils depends on theformation of protofibrils and protofilaments [Uversky et al., 2002d; Uversky, 2003; Qin et al., 2007].The processes of formation of protofilaments and protofibrils are not very well understood.There are some studies show that β-strands of the fibrils runs orthogonal to the fibril direction andare hydrogen-bonded, 4.7 Å apart, to form β-sheet parallel to the axis of the fibril [Quin et al., 2007].X-ray and electron diffraction studies of the α-synuclein fibrils show similar structure [Serpell et al.,2000]. For short peptides the arrangement of the molecules perpendicular to the fibril axis may befully extended [Makin et al., 2005], or, in larger peptides such as Alzheimer’s Aβ, include a hairpinloop [Fraser et al., 1992].
Eisenberg and co-workers proposed eight classes of steric zippers, in which the β-strandsdiffer in their arrangement with respect to orientation of their faces, direction, and whether parallelor antiparallel [Sawaya et al., 2007]. Given the 3.5 Å axial distances between adjacent amino acids inan extended β-strand, the length of the β-strands of α-synuclein calculated in this way exceeds thenarrowest fiber dimension [Serpell et al., 2000]. Thus, models of the arrangement of α-synucleinmolecules with several turn and bend or loop regions were proposed [Der-Sarkissian et al., 2003].The smallest cross dimension of protofilaments to be ~28 Å from both protease-resistant filamentsof trypsin digested fibrils and the protofilaments derived from synuclein 30-103 [Qin et al., 2007]. Apotential model for α-synuclein protofilaments has been proposed by Qin et al. 2007, given that theprotofilament assembled from a polypeptide of ~70 amino acid residues, assuming 3.5 Å axialdistances between adjacent amino acids in an extended β-strand, with 4.8 Å for the interstrand
Figure 2.7: Model of the hierarchical structure and the roles of the
terminal regions in the assembly of α-synuclein fibril. Two
protofilaments are shown interacting via their N- and/or C-terminal
regions to form a protofibril. Subsequently, two protofibrils assemble by
the interaction of C-terminal fragments to form a mature fibril.
[Reproduced from Qin et al., 2007]
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distance in a β-sheet, and that the length of the β-strands should not exceed eight amino acids(connected by β-turns), and the maximum number of strands would be seven, assuming all thestrands are arranged in a β-sheet plane which in turn assemble into fibrils in-register, although itcannot be eliminated the possibility of only five or six strands [Qin et al., 2007]. The model is shownin Figure 2.7, with five strands for clarity. Thus, the fibrillar core of the protofilaments of α-synuclein consists of two β-sheets in which the β-strands are connected by β-turns with sevenstrands per molecule [Qin et al., 2007].
[2.2] Seeded growth of α-synucleinSeeds were prepared by the ultrasonication of fully formed α-synuclein mature fibrils, by applyingelectrical current for total 4 min with intervals of 5 sec. The average height of the seeds wasmeasured around 5 nm; moreover the mature fibrils formed by the initiation of seeds were not sodiversified. We measured the heights of α-synuclein mature fibrils initiated by seeds were between5–7 nm. α-Synuclein aggregation into mature fibrils is very fast when seeds are added to theprotein solution. The exposed living ends of the seeds contains hydrophobic surface [Kim et al.,2007], which show strong binding affinity with partially unfolded monomer. That could be thereason why seeds promote α-synuclein aggregation.Mature fibrils were observed after incubating α-synuclein (80 μM) and α-synuclein seeds(16 μM)  (4:1 molar ratio) in 200 μl of PBS buffer (50 mM, pH 7.4) at 37 °C for 3–6 days withcontinuous shaking at 1000 rpm (see section 3.2.1 in detail for protein  aggregation). Images weretaken in tapping mode AFM, and analyzed by Scanning probe microscopy software, WSxM 5.0 (seesection 3.2.4 in detail for image analysis).We observed the constant height pattern of α-synuclein mature fibrils induced by seeds byincreasing incubation time. The height of α-synuclein mature fibrils induced by seeds wasmeasured around 7 nm. Fibrils growth in a constant height show that the accretion of the α-synuclein monomer to the living ends of the seeds was not random process. Monomeric α-synucleinattach to the living ends of the seeds in a regular pattern. We never observed this kind of regularfibrils growth pattern with constant height in the case of α-synuclein aggregation. The measuredheight of the fibrils around 7 nm was constant by increasing incubation period of α-synuclein in thepresence of seeds. Only lengths of the fibrils were increased by increasing incubation period of α-synuclein in the presence of seeds. These observations suggest that the mature fibrils form directlyby attaching at the living ends of the seeds.
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Figure 2.8: AFM image analysis of α-synuclein mature fibrils induced by seeds. (a) α-Synuclein mature
fibrils (2μm×2μm), (b) α -Synuclein mature fibrils (1μm×1μm), (c) Height profile of α-synuclein mature fibrils
(height measured between 6–8 nm), (d)Kinetics measurement of α-synuclein mature fibrils. The average height
of mature fibrils was measured around ~9 nm, (e) α-Synuclein fragmented fibrils (seeds) (5μm×5μm), (f) α -
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Synuclein fragmented fibril (seeds)(2μm×2μm), (g) Height profile of α -synuclein fragmented fibrils (seeds)
(height measured between 3–9 nm), (h) Kinetics measurement of α-synuclein fragmented fibrils (seeds). The
average height of fragmented fibrils was measured around ~5.5 nm, (i) α-Synuclein mature fibrils initiated by
seeds (2μm×2μm), (j) α-Synuclein mature fibrils initiated by seeds (1μm×1μm), (k) Height profile of α -synuclein
mature fibrils initiated by seeds  (height was measured around ~5.5 nm), (l) Seed dependent aggregation
kinetics of α-synuclein mature fibrils. The average height of mature fibrils was measured around ~5.5 nm, (m) α-
Synuclein mature fibrils initiated by seeds (2μm×2μm), (n) α -Synuclein mature fibrils initiated by seeds
(1μm×1μm), (o) Height profile of α-synuclein mature fibrils initiated by seeds  (height was measured between 5–
6 nm), (p) Seed dependent aggregation kinetics of α-synuclein mature. The average height of mature fibrils was
measured around ~6.5 nm, (q) α-Synuclein mature fibrils initiated by seeds (2μm×2μm), (r) α -Synuclein mature
fibrils initiated by seeds (1μm×1μm), (s) Height profile of α -synuclein mature fibrils initiated by seeds  (height
was measured between 6–7 nm), (t) Seed dependent aggregation kinetics of α-synuclein mature. The average
height of mature fibrils was measured around ~6 nm.
[2.3] α-Synuclein dimers and constructs
[2.3.1] NN-terminal dimer
NN-terminal dimers were formed by adding two cystein mutated α-synuclein at N-terminal region.The cystein mutated α-synuclein at N-terminal region joined together through disulfide bond and itformed NN-terminal dimer.
Figure 2.9: AFM image analysis of NN-terminal dimer. (a) Oligomers of NN-terminal dimer (5μm×5μm), (b)
Oligomers of NN-terminal dimer  (2μm×2μm), (c, d) AFM image of NN-terminal dimer, oligomers, protofibrils
and amorphous aggregates: (c) NN-terminal dimer protofibrils (2μm×2μm), (d) NN-terminal dimer amorphous
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aggregates (2μm×2μm), (e) Height profile of NN-terminal dimer oligomers (height was measured between 5–6
nm), (f) Height profile of single protofibril of NN-terminal dimer ( ~6 nm).
NN-terminal dimer aggregates were observed by incubating NN-terminal dimer (80 μM) in200 μl of PBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (see section3.2.1 in detail for protein aggregation).  Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).The oligomers formed by NN-terminal dimer have height between 5–6 nm. The height of thevery short protofibrils formed by NN-terminal dimer was around 6 nm.Our studies show that the NN-terminal dimer aggregates to form globules, protofibrils andamorphous aggregates. We did not observe mature fibrils in the case of NN-terminal dimeraggregation. It formed globular oligomers of height around 5 nm and very short protofibrils ofheight around 5–6 nm, and then it formed amorphous aggregates. In normal aggregation condition
α-synuclein forms long and mature fibrils of average height around 8 nm. The formation ofamorphous aggregates of NN-terminal dimer indicates that the oligomers and protofibrilsformation does not influenced by disulfide bond present in the NN-terminal dimer, whereas themature fibrils formation influenced by the disulfide bond present in the NN-terminal dimer.  Thefree N- and C-terminal of the α-synuclein plays an important role in the formation of mature fibrils.This is the reason why we never observed mature fibrils of NN-terminal dimer. This indicates thatthe NAC region of NN-terminal dimer plays an important role in the formation of oligomers,protofilaments and protofibrils but not in the formation of mature fibrils.
[2.3.2] CC-terminal dimer
CC-terminal dimers were formed by adding two cystein mutated α-synuclein at C-terminal region.The cystein mutated α-synuclein at C-terminal region joined together through disulfide bond and itformed CC-terminal dimer.
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Figure 2.10: AFM image analysis of CC-terminal dimer. (a) Oligomers of CC-terminal dimer (2μm×2μm),
(b) Oligomers of CC-terminal dimer (1μm×1μm), (c, d) AFM image of oligomers, protofibrils and amorphous
aggregates of CC-terminal dimer: (c) Amorphous aggregates of CC-terminal dimer (2μm×2μm), (d) Protofibrils
of CC-terminal dimer (2μm×2μm),  (e) Height profile of oligomers of CC-terminal dimer (height was measured
between 5–6 nm), (f) Height profile of single protofibril of CC-terminal dimer (height was measured around ~5
nm).
CC-terminal dimer aggregates were observed by incubating CC-terminal dimer (80 μM) in200 μl of PBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (see section3.2.1 in detail for protein aggregation).  Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).The oligomers formed by CC-terminal dimer have height between 5–6 nm. The height of thevery short protofibrils formed by CC-terminal dimer was around 6 nm.Our studies show that the CC-terminal dimer aggregates to form globules, protofibrils andamorphous aggregates. We did not observe mature fibrils in the case of CC-terminal dimeraggregation. It formed globular oligomers of height around 5 nm and very short protofibrils ofheight around 5–6 nm, and then it formed amorphous aggregates. In normal aggregation condition
α-synuclein forms long and mature fibrils of average height around 8 nm. The formation ofamorphous aggregates of CC-terminal dimer indicates that the oligomers and protofibrils formation
- 67 -
does not influenced by disulfide bond present in the CC-terminal dimer, whereas the mature fibrilsformation influenced by the disulfide bond present in the CC-terminal dimer.  The free N- and C-terminal of the α-synuclein plays an important role in the formation of mature fibrils. This is thereason why we never observed mature fibrils of CC-terminal dimer. This indicates that the NACregion of CC-terminal dimer plays an important role in the formation of oligomers, protofilamentsand protofibrils but not in the formation of mature fibrils.
[2.3.3] NC-terminal dimer
NC-terminal dimers were formed by adding α-synuclein through N- and C-terminal region.Methionine of N-terminal region covalently attached through peptide bond with the alanine of C-terminal region.
Figure 2.11: AFM image analysis of NC-terminal dimer. (a) Oligomers of  NC-terminal dimer (2μm×2μm),
(b) Oligomers of  NC-terminal dimer (1μm×1μm), (c) Protofibrils of  NC-terminal dimer (2μm×2μm), (d)
Protofibrils of  NC-terminal dimer (1μm×1μm), (e) Height profile of oligomers of NC-terminal dimer  (height was
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measured between 2–4 nm), (f) Protofibrils height profile of NC-terminal dimer  (height was measured ~6 nm),
(g ) Height profile of single protofibril of NC-terminal dimer (height was measured around ~5 nm), (h) Height
profile of a single left handed twisted NC-terminal dimer mature fibrils (height was measured between 5.5–7.5
nm).  The periodical arrangement of twist in the mature fibrils showed ~2 nm depth and ~130 nm width of the
twisted fibrils. (i) 3D topography of mature fibrils of NC-terminal dimer (height was measured between 5.5–7.5
nm). (J) Kinetics measurement of mature fibrils of NC-terminal dimer. The average height of fully formed mature
fibrils was around ~6 nm.NC-terminal dimer aggregates were observed by incubating NC-terminal dimer (80 μM) in200 μl of PBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (see section3.2.1 in detail for protein aggregation).  Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).In the case of NC-terminal dimer we observed microns long untwisted mature fibrils ofheight around 6 nm and twisted mature fibrils of height around 7 nm.  The periodicity of twistedfibrils in NC-terminal dimer was longer than the periodicity of α-synuclein mature fibrils. We haveobserved around 130 nm long twists in NC-terminal dimer mature fibrils compared to 100 nmtwists in α-synuclein mature fibrils.We observed that the aggregation process of NC-terminal dimer was faster than that of α-synuclein, and it leads to spherical oligomers of height between 2–4 nm. The oligomers of NC-terminal dimer formed faster but smaller than in the case of the α-synuclein. NC-terminal dimerformed microns long mature fibrils that we never observed in the case of α-synuclein. Theseobservations suggest that only one N-terminal region and only one C-terminal region in NC-terminal dimer participates in the formation of protofilaments and protofibrils. This is the reasonwhy NC-terminal dimer formed microns long mature fibrils of height around 5 nm.
[2.3.4] Synucle-Nuclein constructsSynucle-Nuclein constructs were prepared by adding end to end C-terminal region of Synucle (α-synuclein without N-terminal) with N-terminal region of Nuclein (α-synuclein without C-terminal).Synucle-nuclein is a mutated construct of α-synuclein. This construct was prepared by adding twomutated α-synuclein; one α-synuclein with deleted N-terminal region another α-synuclein withdeleted C-terminal region. As the name Synucle-nuclein indicates that synucle does not contains N-terminal region and Nuclein does not contains C-terminal region.
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Figure 2.12: AFM image analysis of Synucle-Nuclein construct. (a) Oligomers of Synucle-Nuclein construct
(2μm×2μm), (b) Oligomers of Synucle-Nuclein construct (1μm×1μm), (c) Mature fibrils of Synucle-Nuclein
construct (2μm×2μm), (d) Mature fibrils of Synucle-Nuclein construct (1μm×1μm), (e) Height profile of
oligomers of Synucle-Nuclein construct (height was measured between 3–6 nm), (f) Height profile of  mature
fibrils of Synucle-Nuclein construct (height of the oligomers varying between 6–8 nm). (g) Height profile of single
fibril of Synucle-Nuclein construct (height was consistent around ~7 nm), (h) Twisted mature fibrils of Synucle-
Nuclein construct (2μm×2μm), (i) Twisted mature fibrils of Synucle-Nuclein construct (1μm×1μm), (j) Height
profile of single left handed twisted mature fibril of Synucle-Nuclein construct (height was measured between 6–
9 nm), (k) Kinetics measurement of Synucle-Nuclein construct. The average height of fully formed mature fibrils
was measured around ~7.5nm.Synucle-Nuclein aggregates were observed by incubating Synucle-Nuclein construct (80μM) in 200 μl of PBS buffer (50 mM, pH 7.4) at 37°C with continuously shaking at 1000 rpm (seesection 3.2.1 in detail for protein aggregation). Images were taken in tapping mode AFM, andanalyzed by Scanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for imageanalysis).
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Synucle-Nuclein construct also formed oligomers and mature fibrils; however theaggregation process was slower than the α-synuclein. Synucle-Nuclein aggregate to formedspherical oligomers of height between 3–6 nm. It formed protofilaments and mature fibrils ofheight between 6–8 nm. Synucle-Nuclein construct formed untwisted mature fibrils of heightaround 6 nm. There are some twists we have observed in Synucle-Nuclein mature fibrils and thelength of twist was smaller than the α-synuclein mature fibrils. In case of Synucle-Nuclein maturefibrils we observed twist around 70 nm in length which was less than the twist in α-synuclein (100nm). As it have been reported previously that the NAC region of the α-synuclein only plays animportant role in the formation of beta sheet (fibrilar core) like structure, and N- and C-terminalregions play an important role in the formation of outer part of the mature fibrils [Qin et al., 2007].In case of Synucle-nuclein construct, two NAC region forms more beta sheet like structure (corepart of the fibril) and thicker fibrils compare to the single NAC region in α-synuclein. This is thereason why Synucle-Nuclein constructs forms mature fibrils of short in length compare to maturefibrils of α-synuclein.
[2.4] Amyloid-beta (Aβ) aggregationWe also studied the aggregation and characterization of Aβ protein. Mature fibrils were generatedby incubating Aβ (80 μM) in 200 μl of PBS buffer (50 mM, pH 7.4) at 37 oC for 3–6 days withcontinuous shaking at 1000 rpm (see section 3.2.1 in detail for protein aggregation). Images weretaken in tapping mode AFM, and analyzed by Scanning probe microscopy software, WSxM 5.0 (seesection 3.2.4 in detail for image analysis).
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Figure 2.13: AFM image analysis of Aβ mature fibrils. (a) Aβ  mature fibrils of height ~4.5 nm
(1.5μm×1.5μm), (b) Aβ  mature fibrils of height ~6 nm (4μm×4μm), (c) Aβ mature fibrils of heig ht ~11 nm
(5μm×5μm), (d, e, f) Height profile of different kind of mature fibrils measured  by nanoscope.It is well known that amyloid-beta aggregates to form insoluble fibrilar object which isnormally associated with the Alzheimer’s disease. We observed three different heights of maturefibrils during Aβ aggregation. First, we measured height of the mature fibrils around 4 nm in 2–3days. Second, we measured height of the mature fibrils around 6 nm in 3–4 days. Third, the verywide and twisted mature fibrils of height around 11 nm were observed in 6–7 days.
[2.5] Effect of 14-3-3η on α-synuclein aggregation
[2.5.1] Interaction between 14-3-3η and α-synuclein monomerIn this case we tried to monitor any possible interaction of 14-3-3η with α-synuclein monomer byNMR and SPR. We did not get any evidence of interaction between monomeric form of α-synucleinand 14-3-3η.NMR experiments were performed in PBS buffer (pH 7.4), with 10% D2O (v/v), 0.02% NaN3(w/v) and 5 mM DTT. [1H-15N]-HSQC spectra were recorded at 283K on a 600 MHz Brukerspectrometer equipped with a triple resonance probe. All NMR data were processed and analyzed
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using NMRPipe (Delaglio F) and Sparky (T. D. Goddard and D. G. Kneller, University of California,San Francisco) software packages.
In Figure 2.14, the blue spectra of α-synuclein (without 14-3-3η) are overlapped with the redspectra of α-synuclein (with 3 fold excess of 14-3-3η). Very marginal differences appeared betweenthese two spectra. This indicates that α-synuclein monomer does not interact with 14-3-3η.We also investigated this interaction by SPR. SPR analyses were carried out in a Biacore Xinstrument (GE Healthcare), with the technical assistance of Dr. Stefania Sarno and Dr. MariaRuzzene (Dipartimento di Chimica Biologica, Universita degli Studi di Padova). The Running Bufferused for experiments on Ni-NTA Sensor Chip was composed of 10 mM HEPES, 150 mM NaCl, 50 μMEDTA, pH 7.4. Chip functionalization was made firstly injecting Ni2+ solution (10 mM HEPES, 150mM NaCl, 50 μM EDTA, 500 μM NiCl2, pH 7.4) to create Ni2+-NTA complex selectively in analysiscell, then 2 μg/ml HT 57–102 or 2.4 μg/ml HT α-synuclein, solubilized in Running Buffer. Forbinding analysis, increasing amount of analyte was injected as required for the calculation of Kd,
Figure 2.14: NMR analysis of interaction
between α-synuclein and 14-3-3η. Overlay of
15N-labeled α-syn [1H–15N] HSQC spectra
recorded with (red) or w/o (blue) 3-fold molar
excess of 14-3-3η. Marginal difference in
spectra. [Courtesy from Bubacco’s lab Padova]
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spanning from 1/10 to 10 times the molar concentration of ligand bounded to analysis cell.Regeneration was performed with Regeneration Buffer (10 ml HEPES, 150 mM NaCl, 350mM EDTA,pH 8.3).
Figure 2.15: SPR analysis of interaction between α-synuclein and 14-3-3η. SPR signal of 1.3 µM 14-3-3η
injection (black arrow) on α-syn functionalized biacore chip (black line) or reference empty cell (red line). No
differences between these two signals can be detected. [Courtesy from Bubacco’s lab Padova]
In Figure 2.15, the red signal of 14-3-3η on reference cell is completely overlapped with the blacksignal of 14-3-3η on α-synuclein functionalized cell.  This also indicates that α-synuclein monomerdoes not interact with 14-3-3η. Both results from NMR and SPR suggest that α-synuclein monomerin the experimental conditions does not have any binding affinity with 14-3-3η.
[2.5.2] Effect of 14-3-3η on α-synuclein mature fibrils
α-Synuclein mature fibrils were generated by incubating α-synuclein (80 μM) in 200 μl of PBSbuffer (50 mM, pH 7.4) at 37 °C for 3–6 days with continuous shaking at 1000 rpm. Fully formedmature fibrils of α-synuclein (80 μM) were incubated with 14-3-3η (20 μM) (4:1 molar ratio) at 37°C for 72 h with continuous shaking at 1000 rpm. Images were taken in tapping mode AFM, andanalyzed by Scanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for imageanalysis). The morphological data for the fibril species were obtained by the averaging a largenumber of individual fibrils (n > 200).
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Figure 2.16: AFM image analysis of α-synuclein mature fibrils obtained in the presence and absence of
14-3-3η. (a) Homogeneous appearance of α-synuclein mature fibrils (2μm×2μm), (b) Kinetics measurement of
α-synuclein mature fibrils of height ~6 nm, (c) Homogeneous appearance of α-synuclein mature fibrils after
incubation with 14-3-3η at 37oC and 1000 rpm for 72 h (2μm×2μm), (d) Kinetics measurement of normal normal
α-synuclein mature fibrils of height ~6 nm.The average height of the α-synuclein mature fibrils was measured around 6 nm. We didnot observe any significant change in morphology and kinetics of the α-synuclein mature fibrilseven after incubating with 14-3-3η. The height of α-synuclein mature fibrils measured afterincubation with 14-3-3η was around 6 nm. This observation suggests that 14-3-3η does not haveany effect also on mature fibrils; moreover 14-3-3η does not interact with α-synuclein maturefibrils.
[2.5.3] Effect of 14-3-3η on α-synuclein oligomersProtein aggregates were generated by incubating 14-3-3η (20 μM) and α-synuclein (80 μM)following different stoichiometric ratio (1:1, 1:4, 1:7, 1:12, 1:20, 1:24, 1:30) in PBS buffer (50 mM,pH 7.4) at 37 oC for 12–24 h with continuous shaking at 1000 rpm. Images were taken in tappingmode AFM, and analyzed by Scanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in
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detail for image analysis). The morphological data for the fibril species were obtained by theaveraging a large number of individual fibrils (n > 200).
Figure 2.17: AFM image of curved object obtained during α-synuclein aggregation in the presence 14-
3-3η by following different stoichiomeric ratio. Different stoichiomeric ratio (1:1, 1:4, 1:7, 1:12, 1:20, 1:24,
1:30) of 14-3-3η and α-synuclein modulate the aggregation process of α-synuclein.
- 76 -
- 77 -
Figure 2.18: Height and curvature distribution of curved object following different stoichiometric ratio
of 14-3-3η and α-synuclein (1:1, 1:4, 1:7, 1:12, 1:20, 1:24, 1:30 1:∞).
These images show that 14-3-3η interacts only with the α-synuclein oligomers. 14-3-3η modulatesthe aggregation pathway of α-synuclein. We observed flexible curved object of height around 2 nmin the presence of 14-3-3η instead of mature and rigid fibrils of height around 8 nm of α-synuclein.All through the study of α-synuclein aggregation in the presence of 14-3-3η proteins, we found that14-3-3η modulates the aggregation pathway of α-synuclein by acting on its aggregationintermediates. We have used different stoichiomeric ratio of 14-3-3η and α-synuclein to study theeffect of 14-3-3η on α-synuclein aggregation. By using 1:4 stoichiometric ratios of 14-3-3η and α-synuclein we observed flexible curved and circular objects of height around 2 nm. At 1:20stoichiometric ratio of 14-3-3η and α-synuclein we observed flexible and segmented objects whichare different from the curved objects. At this level of 14-3-3η in α-synuclein aggregation, α-synuclein forms segmented objects of height between 2–4 nm because of low molar concentrationof 14-3-3η. At 1:24 stoichiometric ratio of 14-3-3η and α-synuclein we observed banana shapedobjects of height between 2–6 nm. At 1:30 stoichiometric ratio of 14-3-3η and α-synuclein weobserved straight and mature fibrils of height around 7 nm.We observed that the different stoichiomeric ratio of 14-3-3η and α-synuclein plays animportant role in aggregation and modulation of aggregation pathway. Higher concentration of 14-3-3η in α-synuclein solution forms more flexible and curved object of height around 2 nm than thelower 14-3-3η concentrated solution. In normal aggregation condition α-synuclein aggregates toform very long and mature fibrils of height around 8 nm. By decreasing concentration of 14-3-3η in
α-synuclein aggregation, α-synuclein forms less curved and more rigid object. Moreover, weobserved that by using 1:24 stoichiomeric ratio of 14-3-3η and α-synuclein, the curvature andflexibility of the intermediate object shifted into the rigid and straight mature fibrils.
Immunogold labeling experiment with curved objectsAFM analysis of curved objects suggests that 14-3-3η influence the α-synuclein aggregationat oligomeric stage. We studied immunogold labeling experiment with α-synuclein and 14-3-3η to understand exactly how 14-3-3η influences the α-synuclein aggregation. First, weprepared immunogold labeled 14-3-3η specific antibodies, and then we incubated immunogoldlabeled 14-3-3η specific antibodies with α-synuclein and 14-3-3η in PBS buffer (50 mM, pH 7.4) at
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37 °C for 12–24 h with continuous shaking at 1000 rpm. Curved object with immunogold labeled14-3-3η specific antibody were analyzed by AFM and TEM.
AFM analysis of immunogold labeled curved object of α-synuclein with 14-3-3η
Figure 2.19: AFM image of immunogold labeled curved object α-synuclein with 14-3-3η in the presence
of 14-3-3η specific antibody. (a, b) 14-3-3η specific antibody (a; 2μm×2μm, b; 1μm×1μm), (c, d) Curved object
in the presence of 14-3-3η specific antibody (2μm×2μm), (e, f) Curved object in the presence of 14-3-3η specific
antibody (1μm×1μm), (g, h) Antibody added to the dried curved surface (2μm×2μm).
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TEM analysis of immunogold labeled curved object of α-synuclein with 14-3-3η
Figure 2.20: TEM image analysis of immunogold labeled curved objects in the presence of 14-3-3η
specific antibody. (a, b ,c) Immunogold labeled 14-3-3η into the curved objects.
We analyzed black spot of immunogold labeled 14-3-3η antibody into the curved objects formed bythe incubation of immunogold labeled 14-3-3η specific antibodies with α-synuclein and 14-3-3η.These observations suggest that 14-3-3η enters into the curved object during α-synucleinaggregation.
Fluorescence emission experimentWe also performed Fluorescence emission experiment to understand intrusion of 14-3-3η into thecurved object. Fluorescence emission experiments were performed to analyze Oregon greenlabeled α-synuclein and Oregon green labeled 14-3-3η into the curved object. Curved objects wereobserved by the incubation of 1:4 ratios of 14-3-3η and α-synuclein at 37 °C with continuousshaking at 1000 rpm 1–2 days.
Figure 2.21: Fluorescence emission spectra of α-synuclein aggregates. (a) Fluorescence emission of
monomer (blue), curved object (pink), mature fibrils (yellow), (b) Fluorescence emission of fluorescent labeled
(α-synuclein+14-3-3η) curved object, overlapped with each other.
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We diluted curved objects in 1 ml of PBS buffer (50 mM, pH 7.4), then we placed curvedobjects in a cuvette inside the fluorescence spectrometer. Then the emission spectrums of curvedobjects were measured separately. First, with Oregon green labeled α-synuclein. Second, withOregon green labeled 14-3-3η. Both emission spectrums overlapped with each other afternormalizing the spectrum.This result suggests that the curved object contains the labeled 14-3-3η and labeled α-synuclein, and in both cases Oregon green labeled 14-3-3η and Oregon green labeled α-synucleingoes along the length of the curved objects.
ThT assay of curved object2.5 mM solutions of ThT in 1X PBS were added with 1μl of ThT solution in 99 μl of curved object forfluorescence spectroscopy experiment. Blank solution was also prepared by adding 1μl of ThT in 99μl of 1X PBS. Both samples were diluted up to 1 ml in MilliQ to perform fluorescence spectroscopyexperiment.
Figure 2.22: Fluorescence spectra of curved object binding with ThT.Both blank and curved objects were placed in a cuvette one by one into the spectrometer.ThT fluorescence emission was measured with excitation at 450 nm and recorded the spectrumbetween 465 nm and 565 nm. The excitation spectra were collected by setting the emissionwavelength to 482 nm. Emission spectra between 440 nm and 565 nm were collected uponexcitation at 450 nm. Excitation and emission spectra in the presence of amyloid fibrils weremeasured with constant ThT and constant curved object concentrations. The decrease in ThT
- 81 -
fluorescence emission with increasing incubation time of curved object indicates that proteinsolution decrease amyloid like fibrilar structure. Normally, amyloid fibril enhances the ThTfluorescence emission by increasing amyloid fibrils concentration in protein solution.
[2.5.4] Effect of 14-3-3η on seeded growth of α-synuclein aggregationProtein aggregates were generated by incubating α-synuclein (80 μM), 14-3-3η (20 μM), α-synuclein seeds (16 μM) (4:1:1) in PBS buffer (50 mM, pH 7.4) at 37 °C for 3–6 days withcontinuous shaking at 1000 rpm. Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).
Figure 2.23: AFM image of seeded growth of α-synuclein aggregation suppressed by 14-3-3η. (a) 14-3-
3η inhibited the aggregation process of α-synuclein (2μm×2μm), (b) In the absence of 14-3-3η α-synuclein and
seeds formed bundles of long and mature fibrils (2μm×2μm).
By studying α-synuclein aggregation in the presence of seeds and 14-3-3η, we observed avery interesting capability of 14-3-3η. 14-3-3η would stop/inhibit seeded growth of α-synuclein byacting/binding at the living ends of the seeds. We observed that 14-3-3η interacted with theliving/exposed ends of the seeds, and it stopped further addition of monomeric α-synuclein to theliving ends of seeds. In normal aggregation condition seeds promote aggregation and it formsmicrons long mature fibrils in a very short period of time. When we added 14-3-3η together with α-synuclein in the presence of seeds, we never observed mature and long fibrils. This observationsuggests that 14-3-3η binds with the living ends of the seeds and it further stops the addition of α-synuclein monomer or oligomers to the living ends of the seeds. By adding at the living ends ofseeds 14-3-3η stops the aggregation process of α-synuclein.
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[2.5.5] Effect of 14-3-3η on NC-terminal dimerCurved objects were generated by incubating NC-terminal α-synuclein dimer (80 μM) and 14-3-3η(20 μM) in PBS buffer (50 mM, pH 7.4) (following 4:1 molar ratio) at 37 °C for 12–24 h withcontinuous shaking at 1000 rpm. Images were taken in tapping mode AFM, and analyzed byScanning probe microscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).
Figure 2.24: AFM image of curved object obtained during the NC-terminal dimer aggregation in the
presence 14-3-3η (a; 2μm×2μm, b&c; 1μm×1μm)14-3-3η also modulated the aggregation pathway of NC-terminal α-synuclein dimer, and itformed curved objects instead of mature fibrils. Like α-synuclein, 14-3-3η modulates theaggregation pathway of NC-terminal α-synuclein dimer. In both cases we observed curved objectsof height around 2 nm. This observation strongly suggests that the acting sight of the 14-3-3ηduring aggregation is an intermediate object (oligomers).
[2.5.6] Effect of 14-3-3η on Aβ aggregationCurved objects were generated by incubating Aβ (80 μM) and 14-3-3η (4:1) in PBS buffer (50 mM,pH 7.4) at 37 °C for 12–24 h with continuous shaking at 1000 rpm. Images were taken in tappingmode AFM, and analyzed by Scanning probe microscopy software, WSxM 5.0 (see section 3.2.4 indetail for image analysis).
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Figure 2.25: AFM image of curved object obtained during the amyloid-beta aggregation in the presence
14-3-3η (a; 2μm×2μm, b&c; 1μm×1μm).14-3-3η also modulated the aggregation process of Aβ. Like α-synuclein and NC-terminaldimer, 14-3-3η modulated the aggregation pathway of Aβ proteins. In this case also we observedcurved objects of height around 2 nm. This observation strongly suggests that the acting sight of the14-3-3η during aggregation is an intermediate object (oligomers).
[2.6] Effect of 14-3-3 γ on α-synuclein aggregation
[2.6.1] Effect of 14-3-3 γ on α-synuclein aggregationWe did experiments also with 14-3-3γ, because it belongs to the family of 14-3-3 group andit shows more than 95% sequence similarity with 14-3-3η. The experiments were carriedout in the presence α-synuclein. Protein aggregates were generated by incubating α-synuclein(80 μM) and 14-3-3γ (20 μM) in PBS buffer (50 mM, pH 7.4) at 37 °C for 3–6 days with continuousshaking at 1000 rpm. Images were taken in tapping mode AFM, and analyzed by Scanning probemicroscopy software, WSxM 5.0 (see section 3.2.4 in detail for image analysis).
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Figure 2.26: AFM image of α-synuclein aggregation unaffected by 14-3-3γ dimer. (a, b) α-Synuclein
formed long and mature fibrils of height ~8 nm in the presence of 14-3-3γ (2μm×2μm). 14 -3-3γ did not show any
effect on α-synuclein aggregation.By studying the effect of 14-3-3γ on α-synuclein aggregation we observed that 14-3-3γ doesnot influence the aggregation process of α-synuclein. The height and diameter of the mature fibrilsobserved by adding 14-3-3γ overlaped with the height and diameter of α-synuclein mature fibrils.We observed height of the α-synuclein mature fibrils in both cases (presence and absence of 14-3-3γ) around 8 nm. This observation suggests that 14-3-3γ does not interact with the α-synuclein.
[2.6.2] Effect of 14-3-3 γ on seeded growth of α-synuclein aggregationProtein aggregates were generated by incubating α-synuclein (80 μM), 14-3-3γ, α-synuclein seeds(4:1:1) in PBS buffer (50 mM, pH 7.4) at 37 °C for 3–6 days with continuous shaking at 1000 rpm.Images were taken in tapping mode AFM, and analyzed by Scanning probe microscopy software,WSxM 5.0 (see section 3.2.4 in detail for image analysis).
Figure 2.27: AFM image of seeded growth of α-synuclein aggregation unaffected by 14-3-3γ. (a, b) 14-3-
3γ did not inhibit the aggregation process of α-synuclein in the presence of seeds (a; 2μm×2μm, b; 1μm×1μm).We did not observe any change in α-synuclein aggregation by adding 14-3-3γ during seededgrowth. This observation suggests that 14-3-3γ does not interact with the α-synuclein seeds duringaggregation.
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[3.1] Cloning, expression and purificationAll the purified proteins (Recombinant α-Synuclein, α-Synuclein mutant and 14-3-3 protein) wereprovided by Bubacco’s lab padova. I was not involved in this work.
[3.2] Atomic force microscopyTapping mode (Imaging) AFM was used for the characterization of all kind of aggregates discussedin this thesis (we have discussed in detail about the mode of action and principle of tapping modeAFM in section 1.2).
[3.2.1] Protein aggregationThere are several ways to get aggregated protein in vitro. In our case, human recombinant α-synuclein (supplied from Bubacco’s lab padova, Italy) was dissolved in double distilled water (Milli-Q, H₂O). After dissolution, it was aliquoted in small eppendorf tube and evacuated to preserveprotein samples for long time period. α-Synuclein aggregates were generated by incubating α-synuclein (80 μM) in 200 μl of PBS buffer (50 mM, pH 7.4) with 0.05% sodium azide to avoidbacterial growth during protein aggregation at 37 °C for 2–15 days with continuous shaking at1000 rpm.
[3.2.2] Sample preparationThe samples for AFM imaging were initiated by depositing 10μl of α-synuclein aggregates on thefreshly cleaved mica (RubyRed Mica Sheets, Electron Microscopy Sciences, Fort Washington, USA)at room temperature (~25 °C). After adsorption for 5 min, the mica surface was gently washed withthe 20–30 drops (1–1.5 ml) of double distilled water (Milli-Q H₂O), to remove excess salts andunbounded proteins from the surface. The sample was dried by condensed nitrogen gas by blowingover the mica surface and stored at room temperature (~25 °C) for imaging.
[3.2.3] AFM imagingAll the images for characterizing α-synuclein aggregates were obtained by Multimode AFM facility(Nanoscope III, Veecco/Digital Instruments, Santa Barbara, CA) with scanner 2795E in a tappingmode. Slandered etched silicon cantilevers (Ultra sharp NSC15/AlBS silicon probes with tip apexradius of ~10 nm, resonant frequency range of AFM cantilever 325 Hz, and number of pixels 512 ×512) were used for imaging in air. All the images were taken at room temperature (~25 °C) and
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~50% humid environment. In order to obtain the images of real height for the aggregates, the forcebetween tips and samples was slightly reduced by increasing the set point value to a maximum. Thescanner parameters were calibrated with Drive amplitude 37.40mV, Drive phase 101.9°, Drivefrequency 337.615 kHz, Z-limit 3.0806 μM, Integral gain 0.5000 and Proportional gain 1.000. Eachsample was imaged in at least five different regions to avoid experimental error.In most experiments, the samples were diluted ~10 times with PBS then equilibrated at RTfor 10’ prior to deposition in an attempt to minimize overlap of individual α-synuclein aggregates.Multiple images from successive depositions were then recorded and digitalized to obtainstatistically significant morphological measurements.[3.2.4] AFM image analysisThe resulting images were processed off-line with free available Scanning probe microscopysoftware (WSxM 5.0 Develop 4.2) [reviewed in Horcas et al., 2007]. The heights and diameters weremeasured with the section profile program.
Overview of WSxMWSxM is a freeware application that is able to read most of the SPM file formats [WSXM freesoftware at www.nanotec.es]. In addition Horcas et al. have developed a tool that is called heuristicopen that opens files with unknown format in a semi automated way, including those files that dueto the lack of a common identifier are not suitable to be recognized as a specific file format. If wehave no information at all about the file that we are trying to open we can simply drag and drop thefile from the Windows explorer into the “heuristic open” window and WSXM will suggest us someparameter/s to open the image using an expert system.
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Figure 3.1: General scheme of WSXM showing the most representative process. [Reproduced from Horcas
et al., 2007]
The algorithm tries to determine parameters such as the number of points, header size, andnumber of images in the files based only on the file size. Almost every known information can befed to the system to improve the reading capabilities including fixed positions for the mostimportant fields in the file header such as number of rows/columns or the real axis amplitudes. Theaim of this work is to briefly describe the structure and performances of WSxM by remarking someof its most outstanding features. Figure 3.7 shows a general scheme of the possibilities of thesoftware.WSxM has been designed to work under MS-Windows; hence all the common features ofthis operating system are naturally included in this software: multiple windows, clipboard copy andpaste, memory management, etc. WSxM is divided into two clearly different parts: image processingand data acquisition (see Figure 3.7 for an overview); while the first part runs in all Windowsversions since MS-Windows 95, the second part only works under MS-Windows NT, 2000, and XP;in this respect we have sacrificed generality to gain stability in data acquisition where system crashmust be avoided as much as possible. WSxM code has been written in C++ using MicrosoftFoundation Classes, a C++ library that allows easy handling of the complex Windows programming.
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C++ is a well-known object oriented programming language with clear advantages in large codes(WSxM has now about half a million code lines).
[3.2.5] Fibril formation and preparation for ultrasonication experimentIn the routinely α-synuclein aggregation experiment we have used 80 μM α-synucleinconcentrations in 200 μl volume of 50 mM PBS with 0.05% sodium azide. After getting maturefibrils of α-synuclein we have diluted it to the 20 μM in 1ml volume of PBS for the ultrasonicationexperiment.
Seeds preparation
α-Synuclein seeds were prepared by the ultrasonication of fully formed mature fibrils (20 μM) fortotal 4 min at the intervals of 5 seconds in ice-cold sample reservoir.
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[4.1] ConclusionsIn my PhD thesis work, I tried to increase our understanding on the amyloidogenic processes ofintrinsically unstructured proteins (e.g., α-Synuclein, α-Synuclein dimers (NN-terminal, CC-terminal, NC-terminal dimer and Synucle-Nuclein construct) and Amyloid-beta protein) and theeffect of 14-3-3η on its aggregation.In order to understand the organization of α-Synuclein monomer during its aggregation andthe formation of mature fibrils, I studied the AFM imaging of α-Synuclein, α-Synuclein dimers andAmyloid-beta protein aggregation. The aggregation mechanism of α-Synuclein dimers has provideda strong indication that only NC-terminal dimer aggregates like that of α-synuclein does and itassembles in an N-C-terminal relative orientation during aggregation. From the aggregation ofSynucle-Nuclein construct has confirmed that NAC region of α-synuclein plays an important role inthe packaging of core part (beta sheet like structure) of mature fibrils. Whereas, Synucle-Nucleinconstruct of α-synuclein formed wider in diameter mature fibrils than the mature fibrils of α-synuclein. This observation of mature fibrils suggest that the double NAC region of Synucle-Nucleinconstruct forms more beta sheet like structure to fill the core part of mature fibrils than that of α-synuclein mature fibrils.The aggregation studies of α-synuclein in the presence of 14-3-3η lead us to their mainconclusion. First, 14-3-3η does not bind to α-synuclein in its monomeric state, and also does notaffect the mature fibers already formed, but targets the most toxic oligomeric species. Second, itaffect the aggregation process of α-Synuclein and NC-terminal dimer by interacting with thegrowing oligomers thus leading to curved and flexible objects, that are most likely off the α-synuclein aggregation pathway. Third, it is able to affect the aggregation process at concentration aslow as those at which are chaperons able to act.In order to understand the effect of 14-3-3η on α-synuclein aggregation, I studied the in
vitro aggregation of α-synuclein in the presence of 14-3-3η by using different biophysicaltechniques. First, I studied by NMR and SPR the monomeric interaction of α-synuclein with 14-3-3η. The NMR and SPR observations show that 14-3-3η does not interact with monomeric form of α-synuclein. To understand the effect of 14-3-3η on α-synuclein mature fibrils, I incubated 14-3-3ηwith α-synuclein mature fibrils. The results from AFM imaging on the α-synuclein mature fibrils inthe presence of 14-3-3 suggest that 14-3-3η does not interact with mature fibrils. Theseobservations suggest that 14-3-3η does not interact with monomeric form of α-synuclein and evennot with mature fibrils.
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In order to understand the effect of 14-3-3η on aggregation intermediates of α-synuclein, Istudied α-synuclein aggregation in the presence of different molar concentration of 14-3-3η. ByAFM imaging at 1:1 stoichiomeric ratio of 14-3-3η and α-synuclein, I observed curved and flexibleobjects of α-synuclein instead of spherical oligomers and mature fibrils. At different stoichiomericratio of 14-3-3η and α-synuclein (1:4, 1:7, 1:12, 1:20, 1:24, 1:30, 1:∞), I found that by lowering themolar concentration of 14-3-3η in an α-synuclein solution, curvature and  flexibility of the curvedobjects decreases. At the 1:24 molar ratio of 14-3-3η and α-synuclein, curvature and flexibility ofthe curved objects shifted into the rigid and straight fibrils. At this point, the single molecule of 14-3-3η modulates the aggregation pathway of 24 molecules of α-synuclein. Being so small the amountof 14-3-3η able to modulate the aggregation behavior of α-synuclein. On the basis of theseobservations, I can infer that 14-3-3η behaves like a chaperone protein.At this point, it is clear that 14-3-3η interacts only with intermediate objects of α-synuclein.Now the question is exactly where and how 14-3-3η modulates the aggregation pathway of α-synuclein? To answer this question, I performed Fluorescence spectroscopy experiment andImmunogold labeling experiment of 14-3-3η with α-synuclein. The fluorescence spectroscopy studyshowed that the 14-3-3η went inside the growing oligomers and protofibrils and it formed curvedobject; this observation was confirmed by the immunogold labeling experiment of 14-3-3η and α-synuclein. These studies then suggest that the 14-3-3η does not interact both with the monomers of
α-synuclein and with mature fibrils. Somehow, 14-3-3η target is in between these two stages of α-synuclein aggregation. I was able to monitor the stage at which 14-3-3η enters into the α-synucleinaggregation, and how in this way it can slow down the aggregation process of α-synuclein andmodulates its whole pathway.The experiments carried out on the α-synuclein aggregation in the presence of fragmented
α-synuclein mature fibrils (seeds) also catalyzed by 14-3-3η. It has demonstrated that 14-3-3ηslows down the accretion of monomeric α-synuclein to the fragmented fibrils of α-synuclein bysticking at the living ends of fragmented fibrils. In this way 14-3-3η inhibits the seeded growth of
α-synuclein. This way a very enlightening experiment that greatly increased our understanding onthe mechanism of action of these proteins that is present in the Lewy bodies, and whose functionand role was not known.
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 “Nanobiotechnology (Satellite Conference), Budapest” Hungary, August 22nd-23rd, 2011.
 “36th FEBS Congress ("Biochemistry for tomorrow's medicine")” Torino, Italy, June 25th-30th,2011.
 “NMR in Biology (Bio-NMR Satellite Meeting)” Torino, June 25th, 2011.
 “CONIAPS-XIII: 13th Conference of International Academy of Physical Sciences” Dehradun,Uttarakhand, India, June 14th-16th, 2011.
 “International Biophysics school on the Molecular Mechanisms of neurodegeneration” Venice,Italy, January 25th-29th, 2010.
 “Course in Genetics and Molecular Pathology of Age Related Neurodegenerative Diseases”European Genetics Foundation, Bologna, Italy, 2010.
 “7th EBSA European Biophysics Congress” Genoa, Italy, July 11th-15th 2009.
 “Two days workshop on Drug Designing and Sequence analysis” Vittal Mallaya ResearchFoundation, Bangalore, India, 2007.
 “National Symposium on Recent Advances in Microbial Biofertilizers, production and
Utilization technology” University of Allahabad, India, 2007.
TALK and POSTER PRESENTATION
 α-Synuclein: A target for Parkinson’s Disease, International symposium cum training
workshop on recent trends in bioinformatics, system biology and biomolecular
interactions, University of Allahabad, India, January 8th-10th 2012. (Invited Talk)
 A Simple and Facile Method for Preparation and Characterization of CdS Nanoparticles bySEM, TEM and AFM. International Symposium on Advanced Complex Inorganic
Nanomaterials, Namur, Belgium, September 11th-14th 2011. (Poster)
 Effect of 14-3-3η on α-synuclein aggregation intermediates. 8th EBSA European
Biophysics Congress, Budapest, Hungary, August 23rd-27th 2011. (Poster)
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 α-synuclein aggregation intermediates influenced by chaperone like protein molecule (14-3-3η). CONIAPS-XIII: 13th Conference of International Academy of Physical Sciences,June 14th-16th 2011, Dehradun, Uttarakhand, India. (Contributed talk)
 14-3-3η acts as a molecular chaperon on α-synuclein aggregation intermediates. 36th FEBS
Congress "Biochemistry for tomorrow's medicine", June 25th-30th 2011, Torino, Italy.(Poster)
 Multi-scale insights into the α-Synuclein aggregation process: from single- moleculemanipulation to mature amyloid fibril characterization. FUNMARCH workshop, CNRBologna, Italy, May 5th-7th 2010. (Contributed Talk)
 Chaperones prevent Protein Aggregation: Mechanism of action investigated by AtomicForce Microscope (AFM). University of Bologna, Italy, May 28th-29th 2010. (Poster)
 Insight into the aggregation process of α-Synuclein: Structural characterization of Synucleindimers. 55th National Meeting of the Italian Society of Biochemistry and Molecular
Biology (SIB), University of Milan, Italy, September 14th-17th 2010. (Poster)
PROFESSIONAL MEMBERSHIP
 Life Member: International Academy of Physical Sciences, Allahabad, India.
 Life Member: The international NanoScience community, Budapest, Hungary.
 Life Member: Blue Planet Society, Allahabad, India.
 Member: Parkinson’s disease online research (Michael J. Fox Foundation)
EXTRA CURRICULAR ACTIVITIES
 Certificate course in Information Technology with Good Grade from National Institute ofInformation Technology (NIIT), Varanasi, India, 2006.
 Yoga training for better Living from B.H.U Varanasi, (Award for best Yoga Practice) India,2006.
 Painting Classes from Allahabad museum (Painting selected for National PaintingExhibition) India, 2007.
PUBLICATIONS
 “Chaperone like protein 14-3-3η interacts with human α-synuclein aggregationintermediates rerouting the intracellular amyloidogenic pathway” – Manuscript Underpreparation.
 “Structure and aggregation of Alpha-Synuclein covalent tandem dimers” – ManuscriptUnder preparation.
 “Insilico Analysis of Interaction between HIV-1 Proteases and derivatives of Cyclic UreaInhibitor and its ADME Toxicity Properties”. Dhruv kumar, D.K.Gupta, Biofrontiers, 1, 2,(2010).
BOOKS and CHAPTER CONTRIBUTION
 Mechanochemistry: Coupling mechanical forces and chemical reactions (Bookchapter) by  Dhruv kumar and Bruno Samori for Molecular Manipulation with Atomic ForceMicroscopy  (Book), CRC Press-publication date: Dec 01 2011, ISBN No –9781439809662
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 Nanophosphors-Nanogold immunoconjugates in Isolation of Biomembranes and in
Drug Delivery (Book chapter) for Recent Advances in Nanomedicine (Book), VBRI Press,
2011, ISBN No-9788192006803
 Insilico analysis of Docking between HIV-1 PR and derivatives of CUI (Docking betweenHIV-1 proteases and cyclic urea inhibitors: A step towards drug designing against AIDS) byDhruv  kumar, Lambert Academic Publishing, 2011, ISBN No –9783844384765
AREA OF INTEREST
 Any area which adds experience and needs attentive mind thinking and an area where Icould come and under their shadow.
PERSONAL DETAIL
 Present Address: Dhruv Kumar, C/o- Prof. Bruno Samori, Via S. Giacomo-11,Nanobioscience lab, Department of Biochemistry, University of Bologna, Bologna, Italy. Pin-40126.
 Permanent Address: S/o Sri Jagdhari Pandey, Vill-Manpura, P.O-Goroul, Dist-Vaishali(Bihar), India. Pin-844118.
 Date of Birth:March 01, 1982.
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